<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Invirase, INN-saquinavir mesilate</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
h4
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	text-decoration:underline;}
h6
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#FF6600;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-link:"Comment Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoPageNumber
	{font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:7.1pt;
	text-indent:-7.1pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.Considrant, li.Considrant, div.Considrant
	{mso-style-name:Consid\00E9rant;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-35.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Table, li.Table, div.Table
	{mso-style-name:Table;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.TextTi12, li.TextTi12, div.TextTi12
	{mso-style-name:"Text\:Ti12";
	mso-style-link:"Text\:Ti12 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TextTi11, li.TextTi11, div.TextTi11
	{mso-style-name:"Text\:Ti11";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Corpsdetex, li.Corpsdetex, div.Corpsdetex
	{mso-style-name:"Corps de tex";
	margin:0in;
	font-size:11.0pt;
	font-family:"Book Antiqua",serif;}
p.HangingIndent, li.HangingIndent, div.HangingIndent
	{mso-style-name:HangingIndent;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TextRef, li.TextRef, div.TextRef
	{mso-style-name:"Text\:Ref";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Annex, li.Annex, div.Annex
	{mso-style-name:Annex;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Description, li.Description, div.Description
	{mso-style-name:Description;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.HdTab1, li.HdTab1, div.HdTab1
	{mso-style-name:"Hd\:Tab\:1";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:85.05pt;
	text-indent:-85.05pt;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Normal11pt, li.Normal11pt, div.Normal11pt
	{mso-style-name:"Normal 11 pt";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Normal11pt0, li.Normal11pt0, div.Normal11pt0
	{mso-style-name:"Normal 11pt";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.TextTi12Char
	{mso-style-name:"Text\:Ti12 Char";
	mso-style-link:"Text\:Ti12";}
p.TextTi10, li.TextTi10, div.TextTi10
	{mso-style-name:"Text\:Ti10";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TextTi12CharChar
	{mso-style-name:"Text\:Ti12 Char Char";
	font-family:"MS Mincho";}
p.AnnexHeading, li.AnnexHeading, div.AnnexHeading
	{mso-style-name:"Annex Heading";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableText10, li.TableText10, div.TableText10
	{mso-style-name:"TableText\:10";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.TextTi12Char1
	{mso-style-name:"Text\:Ti12 Char1";}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;
	font-family:"Arial",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";
	mso-style-link:"Comment Text";
	font-family:"Times New Roman",serif;}
p.HangingIndent0, li.HangingIndent0, div.HangingIndent0
	{mso-style-name:"Hanging Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
I</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='text-transform:uppercase'>Invirase
500&nbsp;</span><span lang=EN-GB>mg </span>film-coated tablets<span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE AND QUANTITATIVE
COMPOSITION</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>One film-coated tablet contains 500&nbsp;mg
of saquinavir as saquinavir mesilate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Excipient </span><u><span lang=EN-GB>with
known effect</span></u><span lang=EN-GB>: Lactose monohydrate: 38.5&nbsp;mg.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>For the full list of excipients, see
section 6.1.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL FORM</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Film-coated tablet<span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Light orange to greyish or brownish orange
film-coated tablet of oval cylindrical biconvex shape with the marking
&quot;SQV 500&quot; on the one side and &quot;ROCHE&quot; on the other side.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</span></b></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Invirase is indicated for the treatment of
HIV-1 infected adult patients. Invirase should only be given in combination
with ritonavir and other antiretroviral medicinal products (see section 4.2).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Therapy with Invirase should be initiated
by a physician experienced in the management of HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>In combination with ritonavir</span></i></p>

<p class=MsoNormal><span lang=EN-GB>The recommended dose of Invirase is
1000&nbsp;mg (2 x 500&nbsp;mg </span>film-coated tablets<span lang=EN-GB>) two
times daily with ritonavir 100&nbsp;mg two times daily in combination with
other antiretroviral agents. For treatment-naive patients initiating treatment
with Invirase/ritonavir, the starting recommended dose of Invirase is
500&nbsp;mg (1 x 500&nbsp;mg film-coated tablet) two times daily with ritonavir
100&nbsp;mg two times daily in combination with other antiretroviral agents for
the first 7 days of treatment. After 7 days, the recommended dose of Invirase
is 1000&nbsp;mg two times daily with ritonavir 100&nbsp;mg two times daily in
combination with other antiretroviral agents. Patients switching immediately
from treatment with another protease inhibitor taken with ritonavir or from a
non-nucleoside reverse transcriptase inhibitor based regimen, except
rilpivirine (see section 4.5), without a wash-out period, should however
initiate and continue Invirase at the standard recommended dose of 1000&nbsp;mg
two times daily with ritonavir 100&nbsp;mg two times daily.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Renal impairment:</span></i></b><b><span
lang=EN-GB><br>
</span></b><span lang=EN-GB>No dosage adjustment is necessary for patients with
mild to moderate renal impairment. Caution should be exercised in patients with
severe renal impairment (see section 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Hepatic impairment:</span></i></b><b><span
lang=EN-GB><br>
</span></b><span lang=EN-GB>No dosage adjustment is necessary for HIV-infected
patients with mild hepatic impairment. </span>No dosage adjustment seems
warranted for patients with moderate hepatic impairment based on limited data.
Close monitoring of safety (including signs of cardiac arrhythmia) and of
virologic response is recommended due to increased variability of the exposure
in this population.<span style='font-size:10.0pt;font-family:"Arial",sans-serif'>
</span><span lang=EN-GB>Invirase/ritonavir is contraindicated in patients with
decompensated hepatic impairment (see sections 4.3 and 4.4).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Paediatric population:</span></i></b></p>

<p class=MsoNormal>The safety and activity of saquinavir boosted with ritonavir
in HIV-infected patients less than 2 years have not been established. No dose
recommendations for paediatric patients &#8805;2 years of age could be
established that are both effective and below thresholds of concern for QT and
PR interval prolongation.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Adults over 60 years:</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>The experience with </span><span
lang=EN-GB>Invirase in adults over 60&nbsp;years </span><span lang=EN-GB>is
limited.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Invirase </span>film-coated tablets<span
lang=EN-GB> should be swallowed whole and taken at the same time as ritonavir
with or after food (see section 5.2). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Invirase is contraindicated in patients with:</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp; hypersensitivity
to the active substance or to any of the excipients</span> listed in section
6.1</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; decompensated
liver disease<span lang=EN-GB> (see section 4.4)</span></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp; congenital
or documented acquired QT prolongation </b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp; electrolyte
disturbances, particularly uncorrected hypokalaemia</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp; clinically
relevant bradycardia</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp; clinically
relevant heart failure with reduced left-ventricular ejection fraction</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp; previous
history of symptomatic arrhythmias</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; concurrent therapy
with any of the following drugs, which may interact and result in potentially
life-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):</p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><b>-&nbsp;&nbsp;&nbsp; drugs
that prolong the QT and/or PR interval</b><b><span lang=EN-GB> (see sections
4.4 and 4.5)</span></b></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; midazolam</span><span lang=EN-GB> </span>administered
orally (for caution on parenterally administered midazolam, see section 4.5)<span
lang=EN-GB>, triazolam (potential for prolonged or increased sedation, respiratory
depression)</span></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; simvastatin, lovastatin (increased risk of
myopathy including rhabdomyolysis)</span></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; ergot alkaloids (e.g. ergotamine,
dihydroergotamine, ergonovine, and methylergonovine) (potential for acute ergot
toxicity)</span></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; rifampicin (risk of severe hepatocellular
toxicity) (see sections 4.4, 4.5, and 4.8)</span></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; quetiapine (risk of coma, see section 4.5). </span></p>

<p class=MsoNormal style='margin-left:49.7pt;text-indent:-.2in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp; lurasidone (potential for serious and/or
life-threatening reactions, see section 4.5)</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special warnings and precautions for use</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Considerations when initiating
Invirase therapy:</span></i></b><span lang=EN-GB> Invirase should not be given
as the sole protease inhibitor. Invirase should only be given in combination
with ritonavir (see section 4.2). Invirase is not recommended for use in
combination with cobicistat as dosing recommendations for this combination have
not been established.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should be informed that saquinavir
is not a cure for HIV infection and that they may continue to acquire illnesses
associated with advanced HIV infection, including opportunistic infections. While
effective viral suppression with antiretroviral therapy has been proven to
substantially reduce the risk of sexual transmission, a residual risk cannot be
excluded. Precautions to prevent transmission should be taken in accordance
with national guidelines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients should also be advised that they
might experience undesirable effects associated with co-administered
medications. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i>Cardiac conduction and
repolarisation abnormalities:</i></b><b> </b></p>

<p class=MsoNormal>Dose-dependent prolongations of QT and PR intervals have
been observed in healthy volunteers receiving ritonavir-boosted Invirase (see
section 5.1).<b> Concomitant use of ritonavir-boosted Invirase with other
medicinal products that prolong the QT and/or PR interval is therefore
contraindicated (see section 4.3).</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Since the magnitude of QT and PR prolongation increases with
increasing concentrations of saquinavir, the recommended dose of
ritonavir-boosted Invirase should not be exceeded. Ritonavir-boosted Invirase
at a dose of 2000&nbsp;mg once daily with ritonavir 100&nbsp;mg once daily has
not been studied with regard to the risk of QT prolongation and is not
recommended. Other medicinal products known to increase the plasma
concentration of ritonavir-boosted Invirase should be used with caution.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Women and elderly patients may be more susceptible to
drug-associated effects on the QT and/or PR interval.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><b><u><span
style='font-family:Symbol'>&middot;</span></u></b><b><u>&nbsp;&nbsp;&nbsp; Clinical
Management:</u></b></p>

<p class=MsoNormal>Consideration should be given for performing baseline and
follow-up electrocardiograms after initiation of treatment, e.g. in patients
taking concomitant medication known to increase the exposure of saquinavir (see
section 4.5). If signs or symptoms suggesting cardiac arrhythmia occur,
continuous monitoring of ECG should be performed. Ritonavir-boosted Invirase
should be discontinued if arrhythmias are demonstrated, or if prolongation
occurs in the QT or PR interval.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Patients initiating therapy with ritonavir-boosted
Invirase</b>:</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'>-&nbsp;&nbsp;&nbsp;&nbsp; An
ECG should be performed on all patients prior to initiation of treatment:
patients with a QT interval &gt;&nbsp;450 msec should not use ritonavir-boosted
Invirase. For patients with a QT interval &lt; 450 msec, an on treatment ECG is
recommended.</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'>-&nbsp;&nbsp;&nbsp;&nbsp; For
treatment-na&iuml;ve patients initiating treatment with Invirase/ritonavir
500/100 mg two times daily for the first 7 days of treatment followed by Invirase
1000 mg two times daily with ritonavir 100 mg two times daily after 7 days and
with a baseline QT interval &lt; 450 msec, an on-treatment ECG is suggested
after approximately 10 days of therapy.</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'>-&nbsp;&nbsp;&nbsp;&nbsp; Patients
demonstrating a subsequent increase in QT-interval to &gt; 480 msec or
prolongation over pre-treatment by &gt; 20 msec should discontinue
ritonavir-boosted Invirase.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>Patients stable on ritonavir-boosted Invirase and
requiring concomitant medication with potential to increase the exposure of
saquinavir or patients on medication with potential to increase the exposure of
saquinavir and requiring concomitant ritonavir-boosted Invirase where no
alternative therapy is available and the benefits outweigh the risks:</b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'>-&nbsp;&nbsp;&nbsp;&nbsp; An
ECG should be performed prior to initiation of the concomitant therapy:
patients with a QT interval &gt; 450 msec should not initiate the concomitant
therapy (see section 4.5).</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'>-&nbsp;&nbsp;&nbsp;&nbsp; For
patients with a baseline QT interval &lt; 450 msec, an on-treatment ECG should
be performed. For patients demonstrating a subsequent increase in QT-interval
to &gt; 480 msec or increase by &gt; 20 msec after commencing concomitant
therapy, the physician should use best clinical judgment to discontinue either
ritonavir-boosted Invirase or the concomitant therapy or both.</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><b><u><span
style='font-family:Symbol'>&middot;</span></u></b><b><u>&nbsp;&nbsp;&nbsp; Essential
Patient Information:</u></b></p>

<p class=MsoNormal><i>Prescribers must ensure that patients</i> <i><span
lang=EN-GB>are fully informed</span></i><span lang=EN-GB> <i>regarding the
following information on cardiac conduction and repolarisation abnormalities: </i></span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp; Patients </span>initiating therapy with
ritonavir boosted Invirase should be warned of the arrhythmogenic risk
associated with QT and PR prolongation and told to report any sign or symptom
suspicious of cardiac arrhythmia (e.g., chest palpitations, syncope,
presyncope) to their physician.</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp; Physicians should enquire about any known
familial history of sudden death at a young age as this may be suggestive of
congenital QT prolongation.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp; Patients should be advised of the
importance not to exceed the recommended dose.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp; Each patient (or patient&#8217;s
caregiver) should be reminded to read the Package Leaflet included in the
Invirase Package.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Liver disease:</span></i></b><span
lang=EN-GB> The safety and efficacy of saquinavir/ritonavir has not been
established in patients with significant underlying liver disorders, therefore
saquinavir/ritonavir should be used cautiously in this patient population.
Invirase/ritonavir is contraindicated in patients with decompensated liver
disease (see section 4.3). Patients with chronic hepatitis B or C and treated
with combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse events. In case of concomitant antiviral
therapy for hepatitis B or C, please refer also to the relevant product
information for these medicinal products.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Patients with pre-existing liver
dysfunction including chronic active hepatitis have an increased frequency of
liver function abnormalities during combination antiretroviral therapy and
should be monitored according to standard practice. If there is evidence of
worsening liver disease in such patients, interruption or discontinuation of
treatment must be considered.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>No dosage adjustment seems warranted for patients with
moderate hepatic impairment based on limited data. Close monitoring of safety
(including signs of cardiac arrhythmia) and of virologic response is
recommended due to increased variability of the exposure in this population
(see sections 4.2 and 5.2). <span lang=EN-GB>There have been reports of
exacerbation of chronic liver dysfunction, including portal hypertension, in
patients with underlying hepatitis B or C, cirrhosis and other underlying liver
abnormalities.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Renal impairment:</span></i></b><span
lang=EN-GB> Renal clearance is only a minor elimination pathway, the principal
route of metabolism and excretion for saquinavir being via the liver.
Therefore, no initial dose adjustment is necessary for patients with renal
impairment. However, patients with severe renal impairment have not been
studied and caution should be exercised when prescribing saquinavir/ritonavir
in this population. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Patients with chronic diarrhoea or
malabsorption:</span></i></b><span lang=EN-GB> No information on boosted
saquinavir and only limited information on the safety and efficacy of unboosted
saquinavir is available for patients suffering from chronic diarrhoea or
malabsorption. It is unknown whether patients with such conditions could
receive subtherapeutic saquinavir levels.</span></p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Paediatric population:</span></i></b><b><span
lang=EN-GB> </span></b>The safety and activity of saquinavir boosted with
ritonavir in HIV-infected patients less than 2 years have not been established.
No dose recommendations for paediatric patients &#8805;2 years of age could be
established that are both effective and below thresholds of concern for QT and
PR interval prolongation. Therefore, use in this population is not recommended.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><i><span lang=EN-GB>Adults over 60 years:</span></i></b><span
lang=EN-GB> The experience with </span><span lang=EN-GB>Invirase in adults over
60&nbsp;years is limited. </span>Elderly patients may be more susceptible to
drug-associated effects on the QT and/or PR interval.</p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Lactose intolerance:</span></i></b><span
lang=EN-GB> Invirase 500&nbsp;mg </span>film-coated tablets<span lang=EN-GB>
contain lactose. Patients with rare hereditary problems of galactose
intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
should not take this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Patients with haemophilia: </span></i></b><span
lang=EN-GB>There have been reports of increased bleeding, including spontaneous
skin haematomas and haemarthroses, in haemophiliac patients type A and B
treated with protease inhibitors. In some patients additional<b> </b>factor
VIII was given. In more than half<b> </b>of the reported cases, treatment with
protease inhibitors was continued<b> </b>or reintroduced if treatment had been
discontinued. A causal relationship has been evoked, although the mechanism of
action has not been elucidated.<b> </b>Haemophiliac patients should therefore
be made aware of the possibility of increased bleeding.</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><i>Weight and metabolic parameters: </i></b>An increase
in weight and in levels of blood lipids and glucose may occur during antiretroviral
therapy. Such changes may in part be linked to disease control and lifestyle.
For lipids, there is in some cases evidence for a treatment effect, while for
weight gain there is no strong evidence relating this to any particular
treatment. For monitoring of blood lipids and glucose reference is made to
established HIV treatment guidelines. Lipid disorders should be managed as
clinically appropriate.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>Osteonecrosis:</span></i></b><span
lang=EN-GB> </span><span lang=EN-GB>Although the aetiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV&#8211;disease and/or
long-term exposure to combination antiretroviral therapy (CART). Patients should
be advised to seek medical advice if they experience joint aches and pain,
joint stiffness or difficulty in movement.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Immune Reactivation Syndrome:</span></i></b><span
lang=EN-GB> In HIV-infected patients with severe immune deficiency at the time
of institution of combination antiretroviral therapy (CART), an inflammatory
reaction to asymptomatic or residual opportunistic pathogens may arise and
cause serious clinical conditions, or aggravation of symptoms. Typically, such
reactions have been observed within the first few weeks or months of initiation
of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or
focal mycobacterial infections, and Pneumocystis carinii pneumonia. Any
inflammatory symptoms should be evaluated and treatment instituted when
necessary.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Autoimmune disorders (such as Graves&#8217;
disease and autoimmune hepatitis) have also been reported to occur in the
setting of immune reactivation; however, the reported time to onset is more
variable and can occur many months after initiation of treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>CYP3A4 Interactions</span></i></b><span
lang=EN-GB>: Saquinavir could interact and modify the pharmacokinetics of other
drugs that are substrates for CYP3A4 and/or P-gp and should be used with
caution. Conversely, other drugs that induce CYP3A4 may also reduce saquinavir
plasma concentrations. Monitoring of saquinavir plasma concentration might be
indicated. See table 1, section 4.5, for drugs known and/or having the
potential to interact with saquinavir and specific recommendations.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Interaction
with ritonavir:</span></i></b><span lang=EN-GB> The recommended dose of
Invirase and ritonavir is 1000&nbsp;mg Invirase plus 100&nbsp;mg ritonavir </span>twice
daily<span lang=EN-GB>. Higher doses of ritonavir have been shown to be
associated with an increased incidence of adverse events. Co-administration of
saquinavir and ritonavir has led to severe adverse events, mainly diabetic
ketoacidosis and liver disorders, especially in patients with pre-existing
liver disease. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Interaction with tipranavir: </span></i></b>Concomitant
use of boosted saquinavir and tipranavir, co-administered with low dose
ritonavir in a dual-boosted regimen, results in a significant decrease in
saquinavir plasma concentrations (see section 4.5). Therefore, the
co-administration of boosted saquinavir and tipranavir, co-administered with
low dose ritonavir, is not recommended.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i>Interaction with HMG-CoA reductase inhibitors:</i></b><i>
</i>Caution must be exercised if Invirase/ritonavir is used concurrently with
atorvastatin, which is metabolised to a lesser extent by CYP3A4. In this
situation a reduced dose of atorvastatin should be considered. If treatment
with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is
recommended with careful monitoring (see section 4.5).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><i>Oral contraceptives:</i></b><i> </i>Because
concentration of ethinyl estradiol may be decreased when co-administered with
Invirase/ritonavir, alternative or additional contraceptive measures should be
used when oestrogen-based oral contraceptives are co-administered (see section
4.5).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><i>Glucocorticoids: </i></b>Concomitant use of boosted
saquinavir and fluticasone or other glucocorticoids that are metabolised by
CYP3A4 is not recommended unless the potential benefit of treatment outweighs
the risk of systemic corticosteroid effects, including Cushing's syndrome and
adrenal suppression (see section 4.5).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><b><i>Interaction with
efavirenz:</i></b> The combination of saquinavir and ritonavir with efavirenz
has been shown to be associated with an increased risk of liver toxicity; liver
function should be monitored when saquinavir and ritonavir are co-administered
with efavirenz. No clinically significant alterations of either saquinavir or efavirenz
concentration were noted in studies in healthy volunteers or in HIV-infected
patients (see section 4.5).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction with other
medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Most drug
interaction studies with saquinavir have been completed with unboosted Invirase
or unboosted saquinavir soft capsules. A limited number of studies have been
completed with ritonavir boosted Invirase or ritonavir boosted saquinavir soft
capsules.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Observations
from drug interaction studies done with unboosted saquinavir might not be
representative of the effects seen with saquinavir/ritonavir therapy.
Furthermore, results seen with saquinavir soft capsules may not predict the
magnitude of these interactions with Invirase/ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The metabolism of saquinavir is mediated by
cytochrome P450, with the specific isoenzyme CYP3A4 responsible for 90&nbsp;%
of the hepatic metabolism. Additionally, <i>in vitro</i> studies have shown
that saquinavir is a substrate and an inhibitor for P-glycoprotein (P-gp).
Therefore, medicinal products that either share this metabolic pathway or
modify CYP3A4 and/or P-gp activity (see <i>&quot;Other potential
interactions&quot;</i>) may modify the pharmacokinetics of saquinavir.
Similarly, saquinavir might also modify the pharmacokinetics of other medicinal
products that are substrates for CYP3A4 or P-gp.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Ritonavir can affect the pharmacokinetics
of other medicinal products because it is a potent inhibitor of CYP3A4 and
P-gp. Therefore, when saquinavir is co-administered with ritonavir,
consideration should be given to the potential effects of ritonavir on other
medicinal products (see the Summary of Product Characteristics for Norvir).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Based on the finding of dose-dependent prolongations of QT
and PR intervals in healthy volunteers receiving Invirase/ritonavir (see
sections 4.3, 4.4 and 5.1), additive effects on QT and PR interval prolongation
may occur. Therefore, concomitant use of ritonavir-boosted Invirase with other
medicinal products that prolong the QT and/or PR interval is contraindicated.
The combination of Invirase/ritonavir with drugs known to increase the exposure
of saquinavir is not recommended and should be avoided when alternative
treatment options are available. If concomitant use is deemed necessary because
the potential benefit to the patient outweighs the risk, particular caution is
warranted (see section 4.4; for information on individual drugs, see Table 1).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Table&nbsp;1: Interactions
and dose recommendations with other medicinal products</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=650
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt0 style='page-break-after:avoid'><b>Medicinal product by
   therapeutic area (dose of Invirase used in study)</b></p>
   </td>
   <td width=240 colspan=3 valign=top style='width:2.5in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt0 style='page-break-after:avoid'><b>Interaction</b></p>
   </td>
   <td width=235 colspan=3 valign=top style='width:176.2pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=Normal11pt0 style='page-break-after:avoid'><b>Recommendations
   concerning co-administration</b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><u>Antiretroviral
  agents<br>
  </u>Nucleoside reverse transcriptase inhibitors (NRTIs)</i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Zalcitabine and/or<br>
  Zidovudine<br>
  <br>
  </p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>No pharmacokinetic
  interaction studies have been completed. </p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Use of
  unboosted saquinavir with zalcitabine and/or zidovudine has been studied in
  adults. Absorption, distribution and elimination of each of the drugs are
  unchanged when they are used together.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Interaction with
  zalcitabine is unlikely due to different routes of metabolism and excretion.<br>
  For zidovudine (200&nbsp;mg every 8 hours) a 25&nbsp;% decrease in AUC was
  reported when combined with ritonavir (300&nbsp;mg every 6 hours). The
  pharmacokinetics of ritonavir remained unchanged.</p>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt;page-break-after:
  avoid'><span lang=EN-GB>No dose adjustment </span>required<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Didanosine<br>
  400&nbsp;mg single dose<br>
  (saquinavir/ritonavir 1600/100&nbsp;mg qd)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Saquinavir AUC </span><span
  style='font-family:Symbol'>&macr;</span><span lang=PT-BR> 30%<br>
  Saquinavir C<sub>max</sub> </span><span style='font-family:Symbol'>&macr;</span><span
  lang=PT-BR> 25%<br>
  Saquinavir C<sub>min </sub></span><span style='font-family:Symbol'>&laquo;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>No dose adjustment required.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Tenofovir disoproxil fumarate 300&nbsp;mg qd<br>
  (<span lang=EN-GB>saquinavir/ritonavir</span> 1000/100&nbsp;mg bid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Saquinavir AUC </span><span
  style='font-family:Symbol'>&macr;</span><span lang=PT-BR> 1%<br>
  Saquinavir C<sub>max</sub> </span><span style='font-family:Symbol'>&macr;</span><span
  lang=PT-BR> 7%<br>
  Saquinavir C<sub>min </sub></span><span style='font-family:Symbol'>&laquo;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>No dose adjustment required.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Non-nucleoside
  reverse transcriptase inhibitors (NNRTIs)</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Delavirdine<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Interaction with
  Invirase/ritonavir not studied.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Delavirdine<br>
  (unboosted saquinavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC &#8593;
  348%.<br>
  There are limited safety and no efficacy data available from the use of this
  combination. In a small, preliminary study, hepatocellular enzyme elevations
  occurred in 13&nbsp;% of subjects during the first several weeks of the
  delavirdine and saquinavir combination (6&nbsp;% Grade 3 or 4).</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Hepatocellular
  changes should be monitored frequently if this combination is prescribed.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Efavirenz 600&nbsp;mg qd<br>
  (<span lang=EN-GB>saquinavir/ritonavir</span> 1600/200&nbsp;mg qd, <i><u>or</u></i><br>
  <span lang=EN-GB>saquinavir/ritonavir 1000/100&nbsp;mg</span><span
  lang=EN-GB> bid, <i><u>or</u></i> </span><br>
  saquinavir/ritonavir 1200/100&nbsp;mg qd)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Saquinavir </span><span
  style='font-family:Symbol'>&laquo;</span><span lang=PT-BR><br>
  Efavirenz </span><span style='font-family:Symbol'>&laquo;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>No dose adjustment required. </span>Liver
  function should be monitored (see section 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Rilpivirine</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>&nbsp;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Switching directly from a
  rilpivirine containing regimen to Invirase/ritonavir is contraindicated as is
  concomitant use due to the potential for life threatening cardiac arrhythmia
  (see sections 4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Nevirapine<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Interaction with
  Invirase/ritonavir not studied.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:12.6pt;text-indent:-12.6pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Nevirapine<br>
  (unboosted saquinavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC <span
  style='font-family:Symbol'>&macr;</span> 24%<br>
  Nevirapine AUC <span style='font-family:Symbol'>&laquo;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>No dose adjustment required.</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=IT>HIV protease inhibitors (PIs)</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Atazanavir
  300&nbsp;mg qd<br>
  (saquinavir/ritonavir 1600/100&nbsp;mg qd)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Saquinavir
  AUC &#8593; 60%<br>
  Saquinavir C<sub>max</sub> &#8593; 42%</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Ritonavir
  AUC &#8593; 41%<br>
  Ritonavir C<sub>max</sub> &#8593; 34%<br>
  Atazanavir </span><span style='font-family:Symbol'>&laquo;</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>No clinical data
  available for the combination of <span lang=EN-GB>saquinavir/ritonavir</span>
  1000/100&nbsp;mg bid and atazanavir.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Fosamprenavir<br>
  700&nbsp;mg bid</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>(saquinavir/ritonavir
  1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC <span
  style='font-family:Symbol'>&macr;</span> 15%<br>
  Saquinavir C<sub>max</sub> <span style='font-family:Symbol'>&macr;</span> 9%</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir C<sub>min</sub>
  <span style='font-family:Symbol'>&macr;</span> 24% (remained above the target
  threshold for effective therapy.)</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment required</span><span lang=EN-GB> for Invirase/ritonavir</span><span
  lang=EN-GB>.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Indinavir<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Low dose ritonavir
  increases the concentration of indinavir.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Increased
  concentrations of indinavir may result in nephrolithiasis.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Indinavir 800&nbsp;mg tid<br>
  (saquinavir 600-1200&nbsp;mg single dose)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC &#8593;
  4.6-7.2 fold<br>
  Indinavir <span style='font-family:Symbol'>&laquo;</span><br>
  No safety and efficacy data available for this combination. Appropriate doses
  of combination not established.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Lopinavir/ritonavir 400/100&nbsp;mg bid<br>
  (<span lang=EN-GB>saquinavir</span> 1000&nbsp;mg bid in combination with 2 or
  3 NRTIs)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Saquinavir <span style='font-family:Symbol'>&laquo;</span><br>
  Ritonavir <span style='font-family:Symbol'>&macr;</span> (effectiveness as
  boosting agent not modified).</p>
  <p class=MsoNormal>Lopinavir <span style='font-family:Symbol'>&laquo;</span>
  (based on historical comparison with unboosted lopinavir)</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;Contraindicated in combination with <span
  lang=EN-GB>Invirase/ritonavir</span> due to the potential for life
  threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; Nelfinavir 1250&nbsp;mg bid<br>
  (saquinavir/ritonavir 1000/100&nbsp;mg bid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC &#8593;
  13%<br>
  (90% CI: 27<span style='font-family:Symbol'>&macr;</span> - 74&#8593;)<br>
  Saquinavir Cmax &#8593; 9%<br>
  (90% CI: 27<span style='font-family:Symbol'>&macr;</span> - 61&#8593; )<br>
  Nelfinavir AUC <span style='font-family:Symbol'>&macr;</span> 6%<br>
  (90% CI: 28<span style='font-family:Symbol'>&macr;</span> - 22&#8593;)<br>
  Nelfinavir Cmax <span style='font-family:Symbol'>&macr;</span> 5%<br>
  (90% CI: 23<span style='font-family:Symbol'>&macr;</span> - 16&#8593;)</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;page-break-after:avoid'>Combination
  not recommended.</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Ritonavir 100&nbsp;mg bid<br>
  (saquinavir 1000&nbsp;mg bid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir &#8593;</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Ritonavir <span
  style='font-family:Symbol'>&laquo;</span><br>
  <span lang=EN-GB>In HIV-infected patients, Invirase or saquinavir soft
  capsules in combination with ritonavir at doses of 1000/100&nbsp;mg twice
  daily provide a systemic exposure of saquinavir over a 24 hour period similar
  to or greater than that achieved with saquinavir soft capsules 1200&nbsp;mg
  three times daily (see section 5.2).</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>This is
  the approved combination regimen. No dose adjustment is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Tipranavir/ritonavir<br>
  (<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Saquinavir C<sub>min</sub> <span style='font-family:
  Symbol'>&macr;</span> 78%<br>
  Dual-boosted protease inhibitor combination therapy in multiple-treatment
  experienced HIV-positive adults.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Concomitant administration of tipranavir,
  co-administered with low dose ritonavir, with saquinavir/ritonavir, is not
  recommended. If the combination is considered necessary, monitoring of the
  saquinavir plasma levels is strongly encouraged (see section 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=IT>HIV fusion inhibitor</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Enfuvirtide<br>
  (saquinavir/ritonavir 1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Saquinavir <span style='font-family:Symbol'>&laquo;</span></p>
  <p class=Normal11pt0>Enfuvirtide <span style='font-family:Symbol'>&laquo;</span><br>
  <span lang=EN-GB>No clinically significant interaction was noted.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>No dose adjustment required.</span></p>
  </td>
 </tr>
 <tr style='height:12.9pt'>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>HIV </span></i></b><b><i>CCR5
  antagonist</i></b></p>
  </td>
 </tr>
 <tr style='height:53.85pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Maraviroc
  100&nbsp;mg bid</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>(saquinavir/ritonavir
  1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Maraviroc AUC<sub>12</sub>
  &#8593; 8.77</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Maraviroc C<sub>max</sub>:
  &#8593; 3.78</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir/ritonavir
  concentrations not measured, no effect is expected.</p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment of saquinavir/ritonavir is required. Dose of maraviroc should be decreased
  to 150&nbsp;mg bid with monitoring.</span></p>
  </td>
 </tr>
 <tr style='height:12.9pt'>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Cobicistat
  containing medicinal products</span></i></b></p>
  </td>
 </tr>
 <tr style='height:53.85pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Cobicistat</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Interaction with
  Invirase/ritonavir not studied. Cobicistat is not recommended in combination
  with regimens containing ritonavir due to similar effects of cobicistat and
  ritonavir on CYP3A.</p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.85pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>It is
  not recommended to coadminister Invirase/ritonavir with cobicistat containing
  products (see section 4.4). <a name="_GoBack"></a></span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><u>Other medicinal
  products<br>
  </u></i></b><b><i><span lang=IT>&nbsp;Alpha-1 adrenoreceptor antagonist</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:66.0pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:66.0pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Alfuzosin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:66.0pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Concomitant use
  of alfuzosin and saquinavir/ritonavir is expected to increase plasma levels
  of alfuzosin.</span></p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:66.0pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Contraindicated
  in combination with Invirase/ritonavir due to potential increase in alfuzosin
  concentration which can result in hypotension and potentially
  life-threatening cardiac arrhythmia.</span></p>
  </td>
 </tr>
 <tr>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i>Antiarrhythmics</i></b></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Bepridil<br>
  Lidocaine (systemic) Quinidine<br>
  Hydroquinidine<br>
  </span>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  of bepridil</span>, systemic<span lang=EN-GB><br>
  lidocaine, quinidine or hydroquinidine may be increased when co-administered
  with Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to
  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=ES>Amiodarone<br>
  flecainide<br>
  propafenone<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Concentrations of </span>amiodarone,
  flecainide or propafenone<span lang=EN-GB> may be increased when
  co-administered with Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>saquinavir/ritonavir</span>
  due to potentially life threatening cardiac arrhythmia (see section 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Dofetilide<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Although
  specific studies have not been performed, co-administration of
  Invirase/ritonavir with medicinal products that are mainly metabolised by
  CYP3A4 pathway may result in elevated plasma concentrations of these
  medicinal products.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to potentially
  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Ibutilide<br>
  Sotalol<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>Invirase/ritonavir</span>
  due to the potential for life threatening cardiac arrhythmia (see sections
  4.3 and 4.4)<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Anticoagulant</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Warfarin</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  of warfarin may be affected </span>when co-administered with
  Invirase/ritonavir<span lang=EN-GB>.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>INR
  (international normalised ratio) monitoring recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Anticonvulsants</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'><span lang=IT>-&nbsp; Carbamazepine Phenobarbital<br>
  Phenytoin<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>These
  medicinal products will induce CYP3A4 and may therefore decrease saquinavir
  concentrations</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Use with caution.</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Monitoring of saquinavir
  plasma concentration is recommended (see section 4.4)</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Antidepressants</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Tricyclic
  antidepressants <br>
  (e.g. amitriptyline, imipramine, clomipramine) (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Invirase/ritonavir</span>
  may increase concentrations of tricyclic antidepressants.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to
  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Maprotiline</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Maprotiline&#8217;s
  metabolism appears to involve the cytochrome P450 isozymes CYP2D6 and CYP 1A2</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Associated
  with a prolongation of QTc intervals.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with Invirase/ritonavir due to potentially life threatening
  cardiac arrhythmia (see sections 4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; <span lang=EN-GB>Nefazodone<u><br>
  </u></span><span lang=IT>(saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with saquinavir/ritonavir not evaluated.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Nefazodone
  inhibits CYP3A4. Saquinavir concentrations may be increased.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Combination not
  recommended. Use with caution due to possible cardiac arrhythmias. Monitoring
  for saquinavir toxicity recommended (see section 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Trazodone<br>
  </span><span lang=IT>(saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Plasma concentrations of
  trazodone may increase.<br>
  Adverse events of nausea, dizziness, hypotension and syncope have been
  observed following coadministration of trazodone and ritonavir.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to
  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr style='height:12.9pt'>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Anti-gout
  preparation</span></i></b></p>
  </td>
 </tr>
 <tr style='height:53.1pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:53.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Colchicine</p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Concomitant use of
  colchicine and saquinavir/ritonavir is expected to increase plasma levels of
  colchicine due to P-gp and/or CYP3A4 inhibition by the protease inhibitor.</p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:53.1pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Because of a potential increase
  of colchicine-related toxicity (neuromuscular events including
  rhabdomyolysis), its concomitant use with saquinavir/ritonavir is not
  recommended, especially in the case of renal or hepatic impairment (see
  section 4.4).</p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Antihistamines</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Terfenadine<br>
  Astemizole<u><br>
  </u></span><span lang=IT>(</span><span lang=EN-GB>saquinavir/ritonavir</span><span
  lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Terfenadine AUC </span>&#8593;, <span
  lang=EN-GB>associated with a prolongation of QTc intervals.<br>
  A similar interaction with astemizole is likely.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with Invirase/ritonavir
  due to the potential for life threatening cardiac arrhythmia (see sections
  4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Mizolastine<br>
  (</span><span lang=EN-GB>saquinavir/ritonavir</span><span lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>Invirase/ritonavir</span>
  due to the potential for life threatening cardiac arrhythmia (see sections
  4.3 and 4.4)<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Anti-infectives</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; <span
  lang=EN-GB>Clarithromycin<u><br>
  </u></span><span lang=IT>(</span><span lang=EN-GB>saquinavir/ritonavir</span><span
  lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; <span
  lang=EN-GB>Interaction with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Clarithromycin is a
  CYP3A4 substrate and is associated with QT prolongation.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Contraindicated
  in combination with Invirase/ritonavir due to the potential for life
  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Clarithromycin<br>
  500&nbsp;mg bid<u><br>
  </u></span>(unboosted saquinavir <span lang=EN-GB>1200&nbsp;mg tid</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Saquinavir
  AUC </span>&#8593; <span lang=EN-GB>177 %<br>
  Saquinavir C<sub>max </sub></span>&#8593; <span lang=EN-GB>187</span><span
  lang=EN-GB> </span><span lang=EN-GB>%<br>
  Clarithromycin AUC </span>&#8593; <span lang=EN-GB>40 %<br>
  Clarithromycin C<sub>max</sub> </span>&#8593; <span lang=EN-GB>40 %</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Erythromycin<u><br>
  </u></span><span lang=IT>(saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0>Erythromycin is a CYP3A4 substrate and is associated
  with QT prolongation.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Erythromycin<br>
  250&nbsp;mg qid<br>
  </span>(unboosted saquinavir <span lang=EN-GB>1200&nbsp;mg tid</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt'>-&nbsp; <span lang=EN-GB>Saquinavir
  AUC </span>&#8593; <span lang=EN-GB>99 %<br>
  Saquinavir C<sub>max </sub></span>&#8593; <span lang=EN-GB>106</span><span
  lang=EN-GB> </span><span lang=EN-GB>%<br>
  <br>
  </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'><span
  lang=IT>Fusidic acid</span></p>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'><span
  lang=IT>(saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Not studied. Co-administration of
  fusidic acid and Invirase/ritonavir can cause increased plasma concentration
  of both fusidic acid and saquinavir/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt'><span
  lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; <span
  lang=EN-GB>Streptogramin antibiotics<u><br>
  </u></span><span lang=IT>(</span><span lang=EN-GB>saquinavir/ritonavir</span><span
  lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Streptogramin
  antibiotics such as quinupristin/dalfopristin inhibit CYP3A4. </span><span
  lang=IT>Saquinavir concentrations may be increased.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Use with caution due to
  possible cardiac arrhythmias. <span lang=EN-GB>Monitoring for saquinavir
  toxicity recommended (see section 4.4).</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'><span
  lang=FR-CH>-&nbsp; Halofantrine<br>
  Pentamidine<br>
  Sparfloxacin<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'><span
  lang=FR-CH>&nbsp;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:.45pt;page-break-after:avoid'>Contraindicated
  in combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=EN-GB>Antifungals</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Ketoconazole 200&nbsp;mg qd<u><br>
  </u>(saquinavir/ritonavir 1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Saquinavir AUC </span><span
  style='font-family:Symbol'>&laquo;</span><span lang=IT><br>
  Saquinavir C<sub>max </sub></span><span style='font-family:Symbol'>&laquo;</span><span
  lang=IT><br>
  Ritonavir AUC </span><span style='font-family:Symbol'>&laquo;</span><span
  lang=IT><br>
  Ritonavir C<sub>max </sub></span><span style='font-family:Symbol'>&laquo;</span><span
  lang=IT><br>
  Ketoconazole AUC &#8593; 168%<br>
  (90% CI 146%-193%)<br>
  Ketoconazole C<sub>max </sub>&#8593; 45%<br>
  (90% CI 32%-59%)</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>No dose adjustment required when
  saquinavir/ritonavir combined with </span><span style='font-family:Symbol'>&pound;</span>&nbsp;200&nbsp;mg/day
  ketoconazole<span lang=EN-GB>. </span>High doses of ketoconazole<br>
  (&gt; 200&nbsp;mg/day) are not recommended.</p>
  </td>
 </tr>
 <tr style='height:76.4pt'>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; Itraconazole<br>
  (saquinavir/ritonavir)</p>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; </p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; Interaction
  with Invirase/ritonavir not studied.</p>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; Itraconazole
  is a moderately potent inhibitor of CYP3A4. An interaction is possible.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Use with caution due to
  possible cardiac arrhythmias. <span lang=EN-GB>Monitoring for saquinavir
  toxicity recommended (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Fluconazole/miconazole</span><u><br>
  </u>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied. Both drugs are CYP3A4 inhibitors and may
  increase the plasma concentration of saquinavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Use with caution due to
  possible cardiac arrhythmias. <span lang=EN-GB>Monitoring for saquinavir
  toxicity recommended (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=EN-GB>Antimycobacterials</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Rifampicin 600&nbsp;mg qd<u><br>
  </u>(saquinavir/ritonavir 1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>In a clinical study 11 of
  17 (65&nbsp;%) healthy volunteers developed severe hepatocellular toxicity
  with transaminase elevations up to &gt;&nbsp;20-fold the upper limit of
  normal after 1 to 5 days of co-administration.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Rifampicin is
  contraindicated in combination with <span lang=EN-GB>Invirase/ritonavir</span><br>
  (see section 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Rifabutin <span lang=IT>150&nbsp;mg
  q3d<br>
  </span>(<span lang=EN-GB>saquinavir/ritonavir</span> 1000/100&nbsp;mg bid) in
  healthy volunteers</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Saquinavir AUC<sub>0-12</sub>
  <span style='font-family:Symbol'>&macr;</span> 13%<br>
  (90% CI: 31<span style='font-family:Symbol'>&macr;</span> - 9&#8593;)<br>
  Saquinavir C<sub>max </sub><span style='font-family:Symbol'>&macr;</span> 15%<br>
  (90% CI: 32<span style='font-family:Symbol'>&macr;</span> - 7&#8593;)<br>
  Ritonavir AUC<sub>0-12</sub> <span style='font-family:Symbol'>&laquo;</span><br>
  (90% CI: 10<span style='font-family:Symbol'>&macr;</span> - 9&#8593;)<br>
  Ritonavir C<sub>max </sub><span style='font-family:Symbol'>&laquo;</span><br>
  (90% CI: 8<span style='font-family:Symbol'>&macr;</span> - 7&#8593;)<br>
  <br>
  Rifabutin active moiety*<br>
  AUC<sub>0-72</sub> &#8593; 134%<br>
  (90% CI 109%-162%)<br>
  Rifabutin active moiety*<br>
  C<sub>max </sub>&#8593; 130%<br>
  (90% CI 98%-167%)</p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'><span lang=FR-CH>Rifabutin AUC<sub>0-72</sub> &#8593;
  53%</span></p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'><span lang=FR-CH>(90% CI 36%-73%)</span></p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'><span lang=FR-CH>Rifabutin C<sub>max </sub>&#8593;
  86%</span></p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'>(90% CI 57%-119%)</p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'>&nbsp;</p>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt;
  page-break-after:avoid'>*&nbsp; Sum of rifabutin + 25-O-desacetyl rifabutin
  metabolite </p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'>To prevent possible
  development of rifabutin resistance in TB and HIV co-infected patients, the
  recommended dose of rifabutin is 150&nbsp;mg every other day or three times
  per week, with the dose of saquinavir/ritonavir unchanged (1000/100&nbsp;mg
  bid). </p>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=MsoNormal style='page-break-after:avoid'>Monitoring of neutropenia
  and liver enzyme levels is recommended due to an expected increase in
  exposure to rifabutin.</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i>Antipsychotics</i></b></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:10.35pt;text-indent:-10.35pt'>&nbsp;</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Lurasidone</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Due to CYP3A inhibition by saquinavir/ritonavir,
  concentrations of lurasidone are expected to increase.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Concomitant administration of Invirase and lurasidone is
  contra-indicated as it may increase lurasidone-related toxicity (see section
  4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Quetiapine</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Due to CYP3A inhibition by saquinavir/ritonavir,
  concentrations of quetiapine are expected to increase.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Concomitant administration of Invirase and quetiapine is
  contra-indicated as it may increase quetiapine-related toxicity. Increased
  plasma concentrations of quetiapine may lead to coma (see sectin 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Pimozide<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Concentrations of
  pimozide may be increased when co-administered with Invirase/ritonavir.</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Pimozide is a CYP3A4
  substrate and is associated with QT prolongation,</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with Invirase/ritonavir due to the potential for life threatening
  cardiac arrhythmia (see sections 4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Clozapine<br>
  Haloperidol</p>
  <p class=Normal11pt0>Chlorpromazine<br>
  Mesoridazine<br>
  Phenothiazines<br>
  Sertindole<br>
  Sultopride<br>
  Thioridazine<br>
  Ziprasidone<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with Invirase/ritonavir
  due to the potential for life threatening cardiac arrhythmia (see sections
  4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Benzodiazepines</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Midazolam
  7.5&nbsp;mg<br>
  single dose (oral)<u><br>
  </u>(saquinavir/ritonavir 1000/100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Midazolam
  AUC &#8593; 12.4 fold<br>
  Midazolam C<sub>max </sub>&#8593; 4.3 fold</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Midazolam t<sub>1/2 </sub>&#8593;
  from 4.7 h to 14.9&nbsp;h<br>
  No data are available on concomitant use of ritonavir boosted saquinavir with
  intravenous midazolam. <span style='font-size:12.0pt'>Studies of other CYP3A
  modulators and i.v. midazolam</span> suggest a possible 3-4 fold increase in
  midazolam plasma levels.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Co-administration of
  Invirase/ritonavir with orally administered<b> </b>midazolam is
  contraindicated (see section 4.3). <span style='color:black'>Caution should
  be used with co-administration of Invirase and parenteral midazolam.<br>
  </span><span lang=EN-GB>If Invirase is co-administered with parenteral
  midazolam it should be done in an intensive care unit (ICU) or similar
  setting which ensures close clinical monitoring and appropriate medical management
  in case of respiratory depression and/or prolonged sedation. Dosage
  adjustment should be considered, especially if more than a single dose of
  midazolam is administered.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Alprazolam<br>
  Clorazepate<br>
  Diazepam<br>
  Flurazepam<u><br>
  </u>(saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  of these medicinal products may be increased when co-administered with
  Invirase/ritonavir. </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Careful
  monitoring of patients with regard to sedative effects is warranted. A
  decrease in the dose of the benzodiazepine may be required.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Triazolam<u><br>
  </u><span lang=PT-BR>(</span><span lang=EN-GB>saquinavir/ritonavir</span><span
  lang=PT-BR>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Concentrations of triazolam may be increased when
  co-administered with <span lang=EN-GB>Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>saquinavir/ritonavir</span>,
  due to the risk of potentially prolonged or increased sedation and
  respiratory depression (see section 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Calcium
  channel blockers</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Felodipine, nifedipine, nicardipine,
  diltiazem, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Concentrations of these medicinal
  products may be increased when co-administered with Invirase/ritonavir. </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Caution is warranted and clinical
  monitoring of patients is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Corticosteroids</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:76.4pt'>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'>-&nbsp; <span lang=EN-GB>Dexamethasone<br>
  </span><span lang=IT>(</span><span lang=EN-GB>saquinavir/ritonavir</span><span
  lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Dexamethasone
  induces CYP3A4 and may </span>decrease<span lang=EN-GB> saquinavir
  concentrations.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt;page-break-after:
  avoid'><span lang=EN-GB>Use with caution. Monitoring of saquinavir plasma
  concentration is recommended (see section 4.4).</span></p>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Fluticasone
  propionate<br>
  50 mcg qid, intranasal<br>
  (ritonavir 100&nbsp;mg bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Fluticasone <span
  lang=EN-GB>propionate</span> &#8593;</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>Intrinsic cortisol <span
  style='font-family:Symbol'>&macr;</span> 86%<br>
  (90% CI 82%-89%)<br>
  <span lang=EN-GB>Greater effects may be expected when fluticasone propionate
  is inhaled. Systemic corticosteroid effects including Cushing&#8217;s
  syndrome and adrenal suppression have been reported in patients receiving
  ritonavir and inhaled or intranasally administered fluticasone propionate;
  this could also occur with other corticosteroids metabolised via the P450 3A
  pathway e.g. budesonide.<br>
  <br>
  Effects of high fluticasone systemic exposure on ritonavir plasma levels yet
  unknown.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Concomitant
  administration of boosted saquinavir and fluticasone propionate and other
  corticosteroids metabolised via the P450 3A pathway (e.g. budesonide) is not
  recommended unless the potential benefit of treatment outweighs the risk of
  systemic corticosteroid effects (see section 4.4).<br>
  Dose reduction of the glucocorticoid should be considered with close
  monitoring of local and systemic effects or a switch to a glucocorticoid,
  which is not a substrate for CYP3A4 (e.g. beclomethasone).<br>
  In case of withdrawal of glucocorticoids progressive dose reduction may have
  to be performed over a longer period.</span></p>
  </td>
 </tr>
 <tr style='height:12.9pt'>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Endothelin
  receptor antagonist</span></i></b></p>
  </td>
 </tr>
 <tr style='height:46.2pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:46.2pt'>
  <p class=Paragraph style='page-break-after:avoid'><span style='font-size:
  11.0pt;font-family:"Times New Roman",serif'>Bosentan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:46.2pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Not studied.
  Concomitant use of bosentan and saquinavir/ritonavir may increase plasma
  levels of bosentan and may decrease plasma levels of saquinavir/ritonavir.</span></p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:46.2pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Dose adjustment
  of bosentan may be required. When bosentan is administered concomitantly with
  saquinavir/ritonavir, the patient&#8217;s tolerability of bosentan should be
  monitored. Monitoring of the patient&#8217;s HIV therapy is also recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><i><u>Medicinal products that are substrates of
  P-glycoprotein</u></i></b></p>
  <p class=Normal11pt0><b><i><span lang=EN-GB>Digitalis glycosides</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT-BR>Digoxin 0.5&nbsp;mg<br>
  single dose</span></p>
  <p class=Normal11pt0><span lang=PT-BR>(saquinavir/ritonavir 1000/100&nbsp;mg
  bid)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Digoxin AUC<sub>0-72</sub> &#8593; 49%</p>
  <p class=Normal11pt0>Digoxin C<sub>max </sub>&#8593; 27%<br>
  <span style='color:black'>Digoxin levels may differ over time. Large
  increments of digoxin may be expected when saquinavir/ritonavir is introduced
  in patients already treated with digoxin.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Caution should be exercised when
  Invirase/ritonavir and digoxin are co-administered. The serum concentration
  of digoxin should be monitored and a dose reduction of digoxin should be
  considered if necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Histamine
  H<sub>2</sub>-receptor antagonist</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:76.4pt'>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'><span lang=FR-CH>-&nbsp; Ranitidine<u><br>
  </u></span><span lang=PT-BR>(</span><span lang=FR-CH>saquinavir/ritonavir</span><span
  lang=PT-BR>)</span></p>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt;
  page-break-after:avoid'><span lang=FR-CH>-&nbsp; Ranitidine<u><br>
  </u></span><span lang=PT-BR>(</span><span lang=FR-CH>unboosted saquinavir</span><span
  lang=PT-BR>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Interaction
  with Invirase/ritonavir not studied.</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=PT-BR>Saquinavir
  AUC </span>&#8593; <span lang=EN-GB>67&nbsp;% </span><span lang=PT-BR><br>
  <br>
  </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:76.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt;page-break-after:
  avoid'><span lang=EN-GB>Increase not thought to be clinically relevant. No
  dose adjustment of saquinavir recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>HMG-CoA
  reductase inhibitors</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Pravastatin<br>
  Fluvastatin<br>
  (</span><span lang=EN-GB>saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Interaction not studied. Metabolism of
  pravastatin and fluvastatin is not dependent on CYP3A4. </span>Interaction
  via effects on transport proteins cannot be excluded.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Interaction unknown. If no alternative
  treatment is available, use with careful monitoring (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Simvastatin<br>
  Lovastatin<u><br>
  </u>(</span><span lang=EN-GB>saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Simvastatin</span> &#8593;&#8593;</p>
  <p class=Normal11pt0><span lang=EN-GB>Lovastatin </span>&#8593;&#8593;</p>
  <p class=Normal11pt0><span lang=EN-GB>Plasma concentrations highly dependent
  on CYP3A4 metabolism. </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Increased concentrations of simvastatin
  and lovastatin have been associated with rhabdomyolysis. These medicinal
  products are contraindicated for use with Invirase/ritonavir (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Atorvastatin</span><span lang=EN-GB><br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Atorvastatin</span><span lang=EN-GB> is
  less dependent on CYP3A4 for metabolism.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>When used with Invirase/ritonavir, the
  lowest possible dose of atorvastatin should be administered and the patient
  should be carefully monitored for signs/symptoms of myopathy (muscle
  weakness, muscle pain, rising plasma creatinine kinase, see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Immunosuppressants</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=PT>Tacrolimus</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Tacrolimus is a substrate of CYP3A4 and P-glycoprotein.
  Concomitant use of tacrolimus and saquinavir/ritonavir is expected to
  increase plasma levels of tacrolimus.</p>
  <p class=Normal11pt0>Tacrolimus may be associated with torsades de pointes<span
  lang=EN-GB>.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Contraindicated in combination with
  Invirase/ritonavir due to the potential for life threatening cardiac
  arrhythmia (see sections 4.3 and 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Ciclosporin<br>
  <br>
  Rapamycin<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Concentrations of these medicinal
  products increase several fold when co-administered with Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Careful therapeutic drug monitoring is
  necessary for these immunosuppressants when co-administered with
  Invirase/ritonavir.</span></p>
  </td>
 </tr>
 <tr style='height:12.9pt'>
  <td width=650 colspan=7 valign=top style='width:487.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.9pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Long-acting
  beta2-adrenergic agonist</span></i></b></p>
  </td>
 </tr>
 <tr style='height:89.85pt'>
  <td width=177 colspan=2 valign=top style='width:133.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.85pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Salmeterol</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.85pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Concomitant use
  of salmeterol and saquinavir/ritonavir is expected to increase plasma levels
  of salmeterol.</span></p>
  </td>
  <td width=237 colspan=4 valign=top style='width:177.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.85pt'>
  <p class=Paragraph style='line-height:normal;page-break-after:avoid'><span
  style='font-size:11.0pt;font-family:"Times New Roman",serif'>Combination not
  recommended as may result in increased risk of cardiovascular adverse events
  associated with salmeterol, including QT prolongation, palpitations, and
  sinus tachycardia (see section 4,4). </span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Narcotic
  analgesics</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Methadone </span><span
  lang=IT>60-120&nbsp;mg qd</span><span lang=IT><br>
  (saquinavir/ritonavir </span><span lang=IT>1000/100&nbsp;mg bid</span><span
  lang=IT>)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Methadone AUC <span
  style='font-family:Symbol'>&macr;</span> <span lang=EN-GB>19&nbsp;%<br>
  (90&nbsp;% CI 9&nbsp;% to 29&nbsp;%)<br>
  None of the 12 patients experienced withdrawal symptoms.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Oral
  contraceptives</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Ethinyl estradiol<br>
  </span>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Concentration of ethinyl estradiol may
  be decreased when co-administered with Invirase/ritonavir. </span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Alternative or additional contraceptive
  measures should be used when oestrogen-based oral contraceptives are
  co-administered (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=EN-GB>Phosphodiesterase type 5 (PDE5)
  inhibitors</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>&nbsp;Sildenafil</p>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>(saquinavir/ritonavir)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sildenafil
  100&nbsp;mg<br>
  (single dose)<br>
  (unboosted saquinavir 1200&nbsp;mg tid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:3.3pt'>Interaction with
  Invirase/ritonavir not studied.</p>
  <p class=Normal11pt0 style='margin-left:3.3pt'>Saquinavir <span
  style='font-family:Symbol'>&laquo;</span><br>
  Sildenafil Cmax &#8593; 140&nbsp;%<br>
  Sildenafil AUC &#8593; 210&nbsp;%</p>
  <p class=Normal11pt0 style='margin-left:3.3pt'>-Sildenafil is a substrate of
  CYP3A4.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt;text-indent:-.45pt'>Contraindicated
  in combination with Invirase/ritonavir due to the potential for life
  threatening cardiac arrhythmia (see sections 4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Vardenafil<u><br>
  </u></span>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  of vardenafil may be increased when co-administered with Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Tadalafil<u><br>
  </u></span>(<span lang=EN-GB>saquinavir/ritonavir</span>)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Concentrations of tadalafil may be
  increased when co-administered with Invirase/ritonavir.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>Invirase/ritonavir</span>
  due to the potential for life threatening cardiac arrhythmia (see sections
  4.3 and 4.4)<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i>Proton pump
  inhibitors</i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Omeprazole
  40&nbsp;mg qd<u><br>
  </u>(saquinavir/ritonavir 1000/100&nbsp;mg bid)</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Saquinavir
  AUC &#8593; 82%<br>
  (90&nbsp;% CI 44-131&nbsp;%)</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Saquinavir
  C<sub>max</sub> &#8593; 75%<br>
  (90&nbsp;% CI 38-123&nbsp;%)<br>
  Ritonavir </span><span style='font-family:Symbol'>&laquo;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Combination not
  recommended.</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Other proton pump
  inhibitors (saquinavir/ritonavir 1000/100&nbsp;mg bid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>No data are available on
  the concomitant administration of Invirase/ritonavir and other proton pump
  inhibitors.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Combination not
  recommended.</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i>Tyrosine kinase
  inhibitors</i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>All tyrosine kinase
  inhibitors with a risk of QT prolongation </p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>e.g. dasatinib,
  </span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>sunitinib</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Interaction with
  Invirase/ritonavir not studied</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with Invirase/ritonavir due to the potential for life threatening
  cardiac arrhythmia (see sections 4.3 and 4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i>Others</i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Ergot
  alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, and
  methylergonovine)<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Invirase/ritonavir may
  increase ergot alkaloids exposure, and consequently, increase the potential
  for acute ergot toxicity.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>The concomitant use of
  Invirase/ritonavir and ergot alkaloids is contra-indicated (see section 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>-&nbsp; Grapefruit
  juice<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Interaction with Invirase/ritonavir not studied.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>-&nbsp; Grapefruit
  juice<br>
  (single dose)<br>
  (unboosted saquinavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Saquinavir &#8593; 50% (normal strength grapefruit
  juice)</p>
  <p class=Normal11pt0>Saquinavir &#8593; 100% (double strength grapefruit
  juice)</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:.45pt'>Increase not thought to be
  clinically relevant. No dose adjustment required.</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>-&nbsp; Garlic
  capsules<br>
  (saquinavir/ritonavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Interaction with Invirase/ritonavir not studied.</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt;text-indent:-9.35pt'>-&nbsp; Garlic
  capsules<br>
  (dose approx. equivalent to two 4&nbsp;g cloves of garlic daily)<br>
  (unboosted saquinavir 1200&nbsp;mg tid)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=FR-CH>Saquinavir AUC </span><span
  style='font-family:Symbol'>&macr;</span><span lang=FR-CH> 51&nbsp;%<br>
  Saquinavir Ctrough </span><span style='font-family:Symbol'>&macr;</span><span
  lang=FR-CH> 49&nbsp;% (8 hours post dose)<br>
  Saquinavir Cmax </span><span style='font-family:Symbol'>&macr;</span><span
  lang=FR-CH> 54&nbsp;%.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:9.35pt'>Patients on saquinavir
  treatment must not take garlic capsules due to the risk of decreased plasma
  concentrations and loss of virological response and possible resistance to
  one or more components of the antiretroviral regimen.</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:dashed windowtext 1.0pt;border-right:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; <span
  lang=EN-GB>St. John&#8217;s wort <br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:3.3pt;page-break-after:avoid'><span
  lang=EN-GB>Interaction with Invirase/ritonavir not studied.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:dashed windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:12.6pt;text-indent:-9.35pt;
  page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='text-indent:-9.35pt;page-break-after:avoid'>-&nbsp; <span
  lang=EN-GB>St. John&#8217;s wort </span><br>
  (unboosted saquinavir)</p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='margin-left:3.3pt;page-break-after:avoid'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
  lang=EN-GB>Plasma levels of unboosted saquinavir can be reduced by
  concomitant use of the herbal preparation St. John&#8217;s wort <i>(Hypericum
  perforatum)</i>. This is due to induction of drug metabolising enzymes and/or
  transport proteins by St. John&#8217;s wort.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Herbal
  preparations containing St. John&#8217;s wort must not be used concomitantly
  with Invirase. If a patient is already taking St. John&#8217;s wort, stop St.
  John&#8217;s wort, check viral levels and if possible saquinavir levels.
  Saquinavir levels may increase on stopping St. John&#8217;s wort, and the
  dose of saquinavir may need adjusting. The inducing effect of St.
  John&#8217;s wort may persist for at least 2 weeks after cessation of
  treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>Other
  potential interactions</span></u></i></b></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=EN-GB>Medicinal
  products that are substrates of CYP3A4</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>e.g.
  dapsone, disopyramide, quinine, fentanyl, and alfentanyl</span></p>
  <p class=Normal11pt0 style='page-break-after:avoid'><u><span
   style='text-decoration:none'>&nbsp;</span></u></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Although
  specific studies have not been performed, co-administration of
  Invirase/ritonavir with medicinal products that are mainly metabolised by
  CYP3A4 pathway may result in elevated plasma concentrations of these
  medicinal products.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to
  potentially life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><b><i><span lang=IT>Gastroenterological medicinal
  products</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>Metoclopramide</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>It is unknown whether medicinal
  products which reduce the gastrointestinal transit time could lead to lower
  saquinavir plasma concentrations.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=IT>Cisapride<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Although
  specific studies have not been performed, co-administration of
  Invirase/ritonavir with medicinal products that are mainly metabolised by
  CYP3A4 pathway may result in elevated plasma concentrations of these
  medicinal products.</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to potentially
  life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=IT>Diphemanil<br>
  (saquinavir/ritonavir)</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0>Contraindicated in combination with <span lang=EN-GB>Invirase/ritonavir</span>
  due to potentially life threatening cardiac arrhythmia (see sections 4.3 and
  4.4)<span lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr>
  <td width=615 colspan=5 valign=top style='width:461.6pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;
  border-right:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b><i><span lang=IT>Vasodilators
  (peripheral)</span></i></b></p>
  </td>
  <td width=16 valign=top style='width:11.8pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=19 valign=top style='width:14.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width=175 valign=top style='width:131.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><span lang=EN-GB>Vincamine
  i.v.</span></p>
  </td>
  <td width=240 colspan=3 valign=top style='width:2.5in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=235 colspan=3 valign=top style='width:176.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Contraindicated in
  combination with <span lang=EN-GB>Invirase/ritonavir</span> due to the
  potential for life threatening cardiac arrhythmia (see sections 4.3 and 4.4)<span
  lang=EN-GB>.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=175 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=236 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=200 style='border:none'></td>
  <td width=16 style='border:none'></td>
  <td width=19 style='border:none'></td>
 </tr>
</table>

<p class=MsoNormal><i><u>Key:</u></i> <span style='font-family:Symbol'>&macr;</span>
reduced, &#8593; increased, <span style='font-family:Symbol'>&laquo;</span>
unchanged, &#8593;&#8593; markedly increased</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility, pregnancy and
lactation</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Pregnancy</span></i></b><b><span
lang=EN-GB>: </span></b><span lang=EN-GB>Evaluation of experimental animal
studies does not indicate direct or indirect harmful effects with respect to
the development of the embryo or foetus, the course of gestation and peri- and
post-natal development. Clinical experience in pregnant women is limited:
Congenital malformations, birth defects and other disorders (without a
congenital malformation) have been reported rarely in pregnant women who had
received saquinavir in combination with other antiretroviral agents. However,
so far the available data are insufficient and do not identify specific risks
for the unborn child. Saquinavir should be used during pregnancy only if the
potential benefit justifies the potential risk to the foetus (see section 5.3).</span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Breast-feeding</span></i></b><b><span
lang=EN-GB>: </span></b><span lang=EN-GB>There are no laboratory animal or
human data available on secretion of saquinavir in breast milk. The potential
for adverse reactions to saquinavir in nursing infants cannot be assessed, and
therefore, breast-feeding should be discontinued prior to receiving saquinavir.
It is recommended that HIV-infected women do not breast feed their infants
under any circumstances in order to avoid transmission of HIV.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to
drive and use machines</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Invirase may
have a minor influence on the ability to drive and use machines. Dizziness,
fatigue and visual impairment have been reported during treatment with
Invirase.</span><span lang=EN-GB> No studies on the effects on the ability to
drive and use machines have been performed.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</span></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><i>a.
Summary of the safety profile</i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Limited data is available from two clinical
studies where the safety of saquinavir soft capsule (1000&nbsp;mg twice daily)
used in combination with low dose ritonavir (100&nbsp;mg twice daily) for at
least 48 weeks was studied in 311 patients. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following adverse events with an at
least possible relationship to ritonavir boosted saquinavir (i.e. adverse
reactions) were reported most frequently: nausea, diarrhoea, fatigue, vomiting,
flatulence, and abdominal pain.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The following adverse events were reported
with the highest severity (grades 3 and 4): anaemia, diabetes mellitus,
diarrhoea, nausea, vomiting and fatigue. </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>For comprehensive dose adjustment recommendations and
drug-associated adverse reactions for ritonavir and other medicinal products
used in combination with saquinavir, physicians should refer to the Summary of
Product Characteristics for each of these medicinal products.</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><i>b.
Tabulated list of adverse reactions</i></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Adverse reactions from two pivotal studies
of saquinavir soft capsule (1000&nbsp;mg twice daily) used in combination with
low dose ritonavir (100&nbsp;mg twice daily) for at least 48 weeks are
summarised in Table 2.&nbsp; Also included are serious and non-serious adverse
reactions from post-marketing spontaneous reports for which a causal
relationship to saquinavir cannot be excluded. </span></p>

<p class=MsoNormal><span style='layout-grid-mode:line'>Adverse reactions are
presented according to the MedDRA system organ classification. The frequency
groupings according to MedDRA convention are: Very common (&#8805; 1/10);
common (&#8805; 1/100 to &lt;1/10); uncommon (&#8805; 1/1,000 to &lt;1/100);
rare (&#8805; 1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known
(frequency cannot be estimated from the available data).</span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-41.15pt;page-break-after:
avoid'><span lang=EN-GB>Table 2: Incidences of Adverse Reactions and marked
laboratory abnormalities in </span><span lang=EN-GB>clinical studies and
post-marketing experience in adult patients</span><span lang=EN-GB>. </span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr>
   <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><i><span
   lang=EN-GB>Body System</span></i></b></p>
   <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
   lang=EN-GB>Frequency of reaction</span></b></p>
   </td>
   <td width=308 valign=top style='width:231.1pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
   lang=EN-GB>Adverse reactions</span></b></p>
   </td>
  </tr>
 </thead>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Blood and the lymphatic system disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Decreased platelet count</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Anaemia, decreased haemoglobin, decreased lymphocyte count,
  decreased white blood cell count</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Neutropenia</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Eye Disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Visual impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Immune System Disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Hypersensitivity&nbsp; </span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Metabolism and nutrition disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Increased blood cholesterol, increased blood triglycerides</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Diabetes mellitus, anorexia, increased appetite</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Decreased appetite</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Psychiatric Disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Decreased libido, sleep disorder</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Nervous System Disorder</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Paraesthesia, peripheral neuropathy, dizziness, dysgeusia,
  headache</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Somnolence, convulsions</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Respiratory, thoracic and mediastinal disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Dyspnoea</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Gastrointestinal disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Diarrhoea, nausea</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Vomiting, abdominal distension, abdominal pain, upper abdominal
  pain, constipation, dry mouth, dyspepsia, eructation, flatulence, lip dry,
  loose stools</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Hepato-biliary disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Very common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>Increased
  alanine aminotransferase, increased aspartate aminotransferase, increased low
  density lipoprotein</p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>Increased
  blood bilirubin, increased blood amylase</p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'>Hepatitis,
  jaundice</p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Renal and urinary disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Increased blood creatinine</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Renal impairment</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Skin and subcutaneous tissue disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Alopecia, dry skin, eczema, lipoatrophy, pruritus, rash</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=FR-CH>Stevens Johnson syndrome, dermatitis bullous</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>Musculoskeletal and connective tissue disorders</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Muscle spasms</span></p>
  </td>
 </tr>
 <tr>
  <td width=616 colspan=2 valign=top style='width:462.15pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><i><span
  lang=EN-GB>General disorders and administration site conditions</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Common</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Asthenia, fatigue, increased fat tissue, malaise</span></p>
  </td>
 </tr>
 <tr>
  <td width=308 valign=top style='width:231.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=308 valign=top style='width:231.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB>Mucosal ulceration</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i>c. Description of
selected adverse reactions</i></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i>Metabolic parameters</i></p>

<p class=MsoNormal>Weight and levels of blood lipids and glucose may increase
during antiretroviral therapy (see section 4.4).</p>

<p class=MsoNormal style='margin-left:.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.1pt'><span lang=EN-GB>There have been
reports of increased bleeding, including spontaneous skin haematomas and
haemarthroses, in haemophilic patients type A and B treated with protease
inhibitors (see section 4.4).</span></p>

<p class=MsoNormal style='margin-left:.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.1pt;text-autospace:none'><span
lang=EN-GB>Increased CPK, myalgia, myositis and rarely, rhabdomyolysis have
been reported with protease inhibitors, particularly in combination with
nucleoside analogues. </span><span lang=EN-GB>Cases of osteonecrosis have been
reported, particularly in patients with generally acknowledged risk factors,
advanced HIV disease or long-term exposure to combination antiretroviral
therapy (CART). The frequency of this is unknown (see section 4.4).</span><span
lang=EN-GB> </span></p>

<p class=MsoNormal style='margin-left:.1pt;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.1pt;text-autospace:none'><span
lang=EN-GB>In HIV-infected patients with severe immune deficiency at the time
of initiation of combination antiretroviral therapy (CART), an inflammatory
reaction to asymptomatic or residual opportunistic infections may arise.</span><span
lang=EN-GB> </span><span lang=EN-GB>Autoimmune disorders (such as
Graves&#8217;disease and autoimmune hepatitis) have also been reported;
however, the reported time to onset is more variable and these events can occur
many months after initiation of treatment (see section 4.4).</span></p>

<p class=MsoNormal style='margin-left:.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>d.
Paediatric population</span></i></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Limited safety
data are available from a paediatric study (NV20911, n=18) in which the safety
of saquinavir hard capsules (50&nbsp;mg/kg bid, not to exceed 1000&nbsp;mg bid)
used in combination with low dose ritonavir oral solution (3&nbsp;mg/kg bid for
body weight from 5 to &lt;15&nbsp;kg, 2.5&nbsp;mg/kg bid for body weight from
15 to 40&nbsp;kg and 100&nbsp;mg bid for body weight &gt;40&nbsp;kg) has been
studied in paediatric patients aged 4 months to 6 years old.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Four patients
in the study experienced five adverse events that were considered related to
trial treatment. These events were vomiting (3 patients), abdominal pain (1
patient) and diarrhoea (1 patient). </span>No unexpected adverse events were
observed in this study.</p>

<p class=MsoNormal style='margin-left:.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal><span lang=EN-GB>Reporting suspected adverse reactions after
authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. </span>Healthcare
professionals are asked to report any suspected adverse reactions via <span
style='background:silver'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a><span lang=EN-GB
style='background:silver'>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There is limited experience of overdose
with saquinavir. Whereas acute or chronic overdose of saquinavir alone did not
result in major complications, in combination with other protease inhibitors,
overdose symptoms and signs such as general weakness, fatigue, diarrhoea,
nausea, vomiting, hair loss, dry mouth, hyponatraemia, weight loss and
orthostatic hypotension have been observed. There is no specific antidote for
overdose with saquinavir. Treatment of overdose with saquinavir should consist
of general supportive measures, including monitoring of vital signs and ECG,
and observations of the patient&#8217;s clinical status. If indicated,
prevention of further absorption can be considered. Since saquinavir is highly
protein bound, dialysis is unlikely to be beneficial in significant removal of
the active substance.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='text-transform:uppercase'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>PHARMACOLOGICAL PROPERTIES</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Pharmaco-therapeutic
group: Antiviral agent, ATC code J05A E01</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Mechanism of action:</span></i></b><i><span
lang=EN-GB> </span></i><span lang=EN-GB style='color:black'>The HIV
protease&nbsp;is an essential viral enzyme required for&nbsp;the specific
cleavage of viral&nbsp;gag and gag-pol polyproteins.
Saquinavir&nbsp;selectively&nbsp;inhibits the HIV protease, thereby preventing
the creation of&nbsp;mature infectious virus particles<strong><span
style='font-weight:normal'>.</span></strong></span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>QT and PR prolongation on
electrocardiogram:</span></i></b><i><span lang=EN-GB> </span></i>The effects of
therapeutic (1000/100&nbsp;mg twice daily) and supra-therapeutic
(1500/100&nbsp;mg twice daily) doses of Invirase/ritonavir on the QT interval
were evaluated in a 4-way crossover, double-blind, placebo- and active-controlled
(moxifloxacin 400&nbsp;mg) study in healthy male and female volunteers aged 18
to 55 years old (N=59). On Day 3 of dosing, ECG measurements were done over a
period of 20&nbsp;hours. The Day 3 timepoint was chosen since the pharmacokinetic
exposure was maximum on that day in a previous 14-day multiple dose
pharmacokinetic study. On Day 3, mean C<sub>max </sub>values were approximately
3&#8209;fold and 4&#8209;fold higher with the therapeutic and supra-therapeutic
doses, respectively, relative to the mean C<sub>max </sub>observed at steady
state with the therapeutic dose administered to HIV patients. On Day&nbsp;3,
the upper 1-sided 95% confidence interval of the maximum mean difference in
pre-dose baseline-corrected QTcS (study specific heart rate corrected QT)
between the active drug and placebo arms was &gt; 10 msec for the two
ritonavir-boosted Invirase treatment groups (see results in Table 3). While the
supra-therapeutic dose of Invirase/ritonavir appeared to have a greater effect
on the QT interval than the therapeutic dose of Invirase/ritonavir, it is not
sure if maximum effect for both doses has been observed. In the therapeutic and
the supra-therapeutic arm 11% and 18% of subjects, respectively, had a QTcS
between 450 and 480 msec. There was no QT prolongation &gt; 500 msec and no
torsade de pointes in the study (see also section 4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt'>Table 3:
Maximum mean of ddQTcS<sup>&#8224;</sup> (msec) on day 3 for therapeutic dose
of Invirase/ritonavir, supra-therapeutic dose of Invirase/ritonavir and active
control moxifloxacin in healthy volunteers in Thorough QT (TQT) Study</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='width:453.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=136 valign=top style='width:102.35pt;border:solid black 1.0pt;
  border-left:none;padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Treatment</span></b></p>
  </td>
  <td width=119 valign=top style='width:89.6pt;border:solid black 1.0pt;
  border-left:none;padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Post-Dose</span></b></p>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Time Point</span></b></p>
  </td>
  <td width=131 valign=top style='width:98.25pt;border:solid black 1.0pt;
  border-left:none;padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Mean </span></b></p>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>ddQTcS</span></b></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:solid black 1.0pt;
  border-left:none;padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Standard Error</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:none;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><b><span style='font-size:11.0pt'>Upper 95%-CI of
  ddQTcS</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=136 valign=top style='width:102.35pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 style='text-align:justify;text-justify:inter-ideograph;
  line-height:14.0pt;page-break-after:avoid'><span style='font-size:11.0pt'>Invirase/ritonavir
  1000/100&nbsp;mg BID</span></p>
  </td>
  <td width=119 valign=top style='width:89.6pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span style='font-size:11.0pt'>12 hours</span></p>
  </td>
  <td width=131 valign=top style='width:98.25pt;border:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>18.86</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>1.91</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>22.01</span></p>
  </td>
 </tr>
 <tr>
  <td width=136 valign=top style='width:102.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 style='text-align:justify;text-justify:inter-ideograph;
  line-height:14.0pt;page-break-after:avoid'><span style='font-size:11.0pt'>Invirase/ritonavir</span></p>
  <p class=TableText10 style='text-align:justify;text-justify:inter-ideograph;
  line-height:14.0pt;page-break-after:avoid'><span style='font-size:11.0pt'>1500/100&nbsp;mg
  BID</span></p>
  </td>
  <td width=119 valign=top style='width:89.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span style='font-size:11.0pt'>20 hours</span></p>
  </td>
  <td width=131 valign=top style='width:98.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>30.22</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>1.91</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>33.36</span></p>
  </td>
 </tr>
 <tr>
  <td width=136 valign=top style='width:102.35pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 style='text-align:justify;text-justify:inter-ideograph;
  line-height:14.0pt;page-break-after:avoid'><span style='font-size:11.0pt'>Moxifloxacin^</span></p>
  </td>
  <td width=119 valign=top style='width:89.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt;
  page-break-after:avoid'><span style='font-size:11.0pt'>4 hours</span></p>
  </td>
  <td width=131 valign=top style='width:98.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>12.18</span></p>
  </td>
  <td width=96 valign=top style='width:1.0in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>1.93</span></p>
  </td>
  <td width=122 valign=top style='width:91.2pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid black 1.0pt;border-right:none;
  padding:0in 3.4pt 0in 3.4pt'>
  <p class=TableText10 align=center style='text-align:center;line-height:14.0pt'><span
  style='font-size:11.0pt'>15.36</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><sup>&#8224;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup></b>Derived
difference of pre-dose baseline corrected QTcS between active treatment and
placebo arms</p>

<p class=MsoNormal>^&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 400&nbsp;mg
was administered only on Day 3</p>

<p class=MsoNormal>Note: QTcS in this study was QT/RR<sup>0.319</sup> for males
and QT/RR<sup>0.337</sup> for females, which are similar to Fridericia&#8217;s correction
(QTcF=QT/RR<sup>0.333</sup>).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In this study, PR interval of &gt; 200 msec was also
observed in 40% and 47% of subjects receiving Invirase/ritonavir
1000/100&nbsp;mg twice daily and 1500/100&nbsp;mg twice daily, respectively, on
Day 3. PR intervals of &gt; 200&nbsp;msec were seen in 3% of subjects in the
active control group (moxifloxacin) and 5% in the placebo arm. The maximum mean
PR interval changes relative to the pre-dose baseline value were 25 msec and 34
msec in the two ritonavir-boosted Invirase treatment groups, 1000/100&nbsp;mg
twice daily and 1500/100&nbsp;mg twice daily, respectively (also see section
4.4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Events of syncope/presyncope occurred at a higher than
expected rate and were seen more frequently under treatment with saquinavir (11
of 13). The clinical relevance of these findings from this study in healthy
volunteers to the use of Invirase/ritonavir in HIV-infected patients is unclear,
but doses exceeding Invirase/ritonavir 1000/100&nbsp;mg twice daily should be
avoided.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The effect of treatment initiation with a dosing regimen of
Invirase/ritonavir 500&nbsp;/100 mg twice daily in combination with 2 NRTIs for
the first 7 days of treatment followed by Invirase/ritonavir 1000&nbsp;/ 100 mg
twice daily in combination with 2 NRTIs in the subsequent 7 days on QTc
interval, PK, and viral load was evaluated in an open-label 2-week
observational study in 23 HIV-1 infected, treatment-na&iuml;ve patients
initiating Invirase/ritonavir therapy. ECG and PK measurements were collected
on Days 3, 4, 7, 10, and 14 of treatment with the modified Invirase/ritonavir
treatment. The primary study variable was maximal change from dense predose
baseline in QTcF (&#916;QTcFdense). The modified Invirase/ritonavir regimen
reduced mean maximum &#916;QTcF<sub>dense</sub> in the first week of treatment
compared with the same value in healthy volunteers receiving the standard
Invirase/ritonavir dosing regimen in the TQT study on Day 3, (Table 4) based on
cross-study comparison in a different population. Only 2/21 (9%) patients
across all study days had maximum QTcF change from dense predose baseline
&#8805; 30 ms following administration of the modified Invirase/ritonavir
regimen in the treatment-na&iuml;ve HIV-1 infected patient population; and the
maximum mean change from dense predose baseline in QTcF was &lt; 10 ms across
all study days. These results suggest that the QTc liability is reduced with
the modified Invirase/ritonavir dosing regimen, based on a cross-study
comparison in a different population (Table 4). The proportion of patients with
a reported PR interval prolongation &gt; 200 ms in this study ranged from 3/22
(14%) (day 3) to 8/21 (38%) (day14).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Following the modified Invirase/ritonavir regimen,
saquinavir exposure during the first week peaked on Day 3 and declined to the
lowest exposure on Day 7 with ritonavir induction effects, while Day 14
saquinavir PK parameters (following full doses of Invirase/ritonavir in the
second week) approached the range of historical mean values for saquinavir
steady-state values in HIV-1 infected patients (Table 9). Mean Invirase C<sub>max</sub>
with the modified Invirase/ritonavir regimen was approximately 53-83% lower
across study days in the HIV-1 infected patients relative to the mean C<sub>max</sub>
achieved in healthy volunteers in the TQT study on Day 3. Continuous declines
in HIV-RNA were observed in all treatment-na&iuml;ve patients receiving the
modified Invirase/ritonavir dosing regimen over the 2-week treatment period,
suggesting HIV viral suppression during the time of the study. No long-term
efficacy was evaluated with the modified regimen. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Table 4: Summary of Electrocardiogram Parameters following administration
of the Modified Invirase/ritonavir Regimen in Treatment Na&iuml;ve HIV-1
infected Patients initiating treatment with Invirase/ritonavir</p>

<div align=right>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=630
 style='width:472.7pt;border-collapse:collapse'>
 <tr style='height:31.9pt'>
  <td width=164 valign=top style='width:122.9pt;border:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Parameter</b></p>
  </td>
  <td width=72 valign=top style='width:.75in;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Day 3</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=22)</b></p>
  </td>
  <td width=72 valign=top style='width:.75in;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Day 4</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=72 valign=top style='width:.75in;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Day 7</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Day 10</b></p>
  <p class=MsoNormal><b>1000/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>Day 14</b></p>
  <p class=MsoNormal><b>1000/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=88 valign=top style='width:66.3pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:31.9pt'>
  <p class=MsoNormal><b>TQT Study </b></p>
  <p class=MsoNormal><b>Day 3*</b></p>
  <p class=MsoNormal><b>(n=57)</b></p>
  </td>
 </tr>
 <tr style='height:19.95pt'>
  <td width=164 valign=top style='width:122.9pt;border:solid black 1.0pt;
  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>Mean Maximal &#916;QTcF<sub><span
  style='position:relative;top:3.5pt'>dense</span></sub>&nbsp;ms (SD)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>3.26 &plusmn; 7.01</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>0.52 &plusmn; 9.25 </span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>7.13 &plusmn; 7.36</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>11.97 &plusmn; 11.55</span></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>7.48 &plusmn; 8.46</span></p>
  </td>
  <td width=88 valign=top style='width:66.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:19.95pt'>
  <p class=MsoNormal><span style='color:black'>32.2 &plusmn; 13.4</span></p>
  </td>
 </tr>
 <tr style='height:11.5pt'>
  <td width=164 valign=top style='width:122.9pt;border:solid black 1.0pt;
  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>Patients with maximal &#916;QTcF<sub><span
  style='position:relative;top:3.5pt'>dense</span></sub>&nbsp;&#8805; 30 ms (%)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>0</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>0</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>0</span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>2/21 (9%)</span></p>
  </td>
  <td width=78 valign=top style='width:58.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>0</span></p>
  </td>
  <td width=88 valign=top style='width:66.3pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:11.5pt'>
  <p class=MsoNormal><span style='color:black'>29/57 (51%)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal>*Historical data from the thorough QT study conducted in
healthy volunteers</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><i><span lang=EN-GB>Antiviral activity in vitro:</span></i></b><span
lang=EN-GB> </span><span style='color:black'>Saquinavir&nbsp;demonstrates
antiviral activity against a panel of laboratory strains and clinical isolates
of HIV-1 with typical EC<sub>50</sub> and&nbsp;EC<sub>90</sub> values in the
range 1-10 nM and 5-50 nM, respectively, </span><span lang=EN-GB
style='color:black'>with no apparent difference between subtype B and non-B
clades. The corresponding serum (50% human serum) adjusted EC<sub>50</sub>
ranged from 25-250 nM. Clinical isolates of HIV-2 demonstrated EC<sub>50</sub>
values in the range of 0.3-2.4 nM.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i>Resistance</i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Antiviral activity
according to baseline genotype and phenotype:</i></p>

<p class=MsoNormal style='page-break-after:avoid'><em>&nbsp;</em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span style='font-style:
normal'>Genotypic and phenotypic clinical cut-offs predicting the clinical
efficacy of ritonavir boosted saquinavir have been derived from retrospective
analyses of the RESIST 1 and 2 clinical studies and analysis of a large
hospital cohort (Marcelin et al 2007). </span></em></p>

<p class=MsoNormal><em><span style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span style='font-style:normal'>Baseline saquinavir
phenotype (shift in susceptibility relative to reference, PhenoSense Assay) was
shown to be a predictive factor of virological outcome. Virological response
was first observed to decrease when the fold shift exceeded 2.3-fold; whereas
virological benefit was not observed when the fold shift exceeded 12-fold.</span></em></p>

<p class=MsoNormal><em><span style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal><em><span style='font-style:normal'>Marcelin et al (2007)
identified nine protease codons (L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V,
G73S/T, V82A/F/S/T, I84V, L90M) that were associated with decreased virological
response to saquinavir/ritonavir (1000/100&nbsp;mg twice daily) in 138
saquinavir naive patients. The presence of 3 or more mutations was associated
with reduced response to saquinavir/ritonavir.</span></em><em><span
style='font-style:normal'> </span></em><em><span style='font-style:normal'>The
association between the number of these saquinavir-associated resistance
mutations and virological response was confirmed in an independent clinical
study (RESIST 1 and 2) involving a more heavily treatment experienced patient
population, including 54% who had received prior saquinavir (p=0.0133, see
Table&nbsp;5). The G48V mutation, previously identified </span></em><em>in
vitro</em><em><span style='font-style:normal'> as a saquinavir signature
mutation, was present at baseline in virus from three patients, none of whom
responded to therapy.</span></em></p>

<p class=MsoNormal><em><span style='font-style:normal'>&nbsp;</span></em></p>

<p class=MsoNormal style='margin-left:39.15pt;text-indent:-39.15pt;page-break-after:
avoid'><em><span style='font-style:normal'>Table 5: Virological response to
saquinavir/ritonavir stratified by the number of baseline saquinavir-associated
resistance mutations</span></em></p>

<p class=MsoNormal style='page-break-after:avoid'><em><span lang=EN-GB
style='font-style:normal'>&nbsp;</span></em></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=93 rowspan=3 valign=top style='width:70.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Number of Saquinavir Associated Resistance Mutations
  at Baseline*</span></b></p>
  </td>
  <td width=235 colspan=2 style='width:2.45in;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Marcelin et al (2007)</span></b></p>
  </td>
  <td width=242 colspan=2 style='width:181.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>RESIST 1 &amp; 2</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=235 colspan=2 style='width:2.45in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>SQV Naive Population</span></b></p>
  </td>
  <td width=242 colspan=2 style='width:181.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>SQV Naive/Experienced Population</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>N=138</span></b></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Change in Baseline Plasma HIV-1 RNA at<br>
  <u>Weeks 12-20</u></span></b></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>N=114</span></b></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Change in Baseline Plasma HIV-1 RNA at<br>
  <u>Week 4</u></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>0</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>35</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-2.24</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>2</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-2.04</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>1</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>29</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-1.88</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>3</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-1.69</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>2</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>24</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-1.43</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>14</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-1.57</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>3</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>30</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.52</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>28</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-1.41</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>4</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>9</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.18</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>40</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.75</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>5</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>6</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.11</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>17</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.44</span></p>
  </td>
 </tr>
 <tr style='height:16.15pt'>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>6</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>5</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-0.30</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>9</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:16.15pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>0.08</span></p>
  </td>
 </tr>
 <tr>
  <td width=93 style='width:70.0pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>7</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>0</span></p>
  </td>
  <td width=176 style='width:132.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>-</span></p>
  </td>
  <td width=59 style='width:44.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>1</span></p>
  </td>
  <td width=183 style='width:137.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=TextTi12 align=center style='margin-bottom:0in;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='font-size:
  11.0pt'>0.24</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:24.0pt;text-indent:-24.0pt'><span
lang=EN-GB style='font-size:10.0pt'>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><em><span
lang=EN-GB>Saquinavir Mutation Score Mutations: L10F/I/M/R/V, I15A/V,
K20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M</span></em></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><b><i><span
lang=EN-GB>Clinical results from studies with treatment na&iuml;ve and
experienced patients</span></i></b></p>

<p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>In the MaxCmin1 study, the safety and
efficacy of saquinavir soft capsules/ritonavir 1000/100&nbsp;mg twice daily
plus 2 NRTIs/<span style='layout-grid-mode:line'>Non-Nucleoside Reverse
Transcriptase Inhibitors (</span>NNRTIs) was compared to indinavir/ritonavir
800/100&nbsp;mg twice daily plus 2 NRTIs/NNRTIs in over 300 (both protease
inhibitor treatment na&iuml;ve and experienced) subjects. The combination of
saquinavir and ritonavir exhibited a superior virological activity compared
with the indinavir and ritonavir arm when switch from the assigned treatment
was counted as virological failure. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In the MaxCmin2 study, the safety and
efficacy of saquinavir soft capsules/ritonavir 1000/100&nbsp;mg twice daily
plus 2&nbsp;NRTIs/NNRTIs was compared with lopinavir/ritonavir 400/100&nbsp;mg
twice daily plus 2 NRTIs/NNRTIs in 324 (both protease inhibitor treatment
na&iuml;ve and experienced) subjects. None of the subjects in the
lopinavir/ritonavir arm had been exposed to lopinavir prior to randomisation
whereas 16 of the subjects in the saquinavir/ritonavir arm had previously been
exposed to saquinavir.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Table&nbsp;6: Subject
Demographics MaxCmin1 and MaxCmin2<sup>&#8224;</sup></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.0pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>MaxCmin1</span></b></p>
  </td>
  <td width=180 colspan=2 valign=top style='width:135.0pt;border-top:solid black 1.0pt;
  border-left:none;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>MaxCmin2</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border-top:none;border-left:
  solid black 1.0pt;border-bottom:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>SQV/r</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>IDV/r</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>SQV/r</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border:none;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>LPV/r</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>N=148</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>N=158</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>N=161</span></b></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><b><span lang=EN-GB>N=163</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Sex</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Male</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>82%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>74%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>81%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>76%</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Race
  (White/Black/Asian) %</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>86/9/1</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>82/12/4</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>75/19/1</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>74/19/2</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Age,
  median, yrs</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>39</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>40</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>40</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>40</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>CDC
  Category C (%)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>32%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>28%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>32%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>31%</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Antiretroviral
  na&iuml;ve (%)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>28%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>22%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>31%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>34%</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>PI
  na&iuml;ve (%)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>41%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>38%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>48%</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>48%</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>Median
  Baseline HIV-1 RNA, log<sub>10</sub> copies/ml (IQR)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>4.0</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>(1.7-5.1)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>3.9</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>(1.7-5.2)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>4.4 </span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>(3.1-5.1)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>4.6</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=ES>(3.5-5.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=216 valign=top style='width:2.25in;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>Median
  Baseline CD4<sup>+</sup> Cell Count, cells/mm<sup>3</sup> (IQR)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>272</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(135-420)
  </span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>280</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(139-453)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>241</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(86-400)</span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>239</span></p>
  <p class=Normal11pt style='page-break-after:avoid'><span lang=EN-GB>(95-420)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><sup>&#8224; </sup>data from clinical study report</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Table&nbsp;7: Outcomes at
Week 48 MaxCmin1 and MaxCmin2<sup>&#8224;</sup></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=619
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid;height:18.4pt'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-bottom:none;padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>Outcomes</b></p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>MaxCmin1</b></p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:18.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>MaxCmin2</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>SQV/r</b></p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>IDV/r</b></p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>SQV/r</b></p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'><b>LPV/r</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Initiated assigned
  treatment, </p>
  <p class=Normal11pt0 style='page-break-after:avoid'>n (%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>148</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(94%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>158</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(99%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>161</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(94%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>163</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(98%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Discontinued assigned
  treatment, n (%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>40</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(27%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>64</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(41%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>48</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(30%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>23</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>(14%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.01</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.001</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Virological failure
  ITT/e*<sup>#</sup></p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>36/148 (24%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>41/158 (26%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>53/161 (33%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>29/163 (18%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.76</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.002</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Proportion with VL &lt;
  50 copies/ml at week 48, ITT/e<sup>#</sup></p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>97/144<br>
  (67%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>106/154<br>
  (69%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>90/158<br>
  (57%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>106/162<br>
  (65%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.35pt'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P &gt;0.05<sup>&#8225;</sup></p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.35pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.12</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Proportion with VL &lt;
  50 copies/ml at week 48,</p>
  <p class=Normal11pt0 style='page-break-after:avoid'>On Treatment</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>82/104<br>
  (79%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>73/93<br>
  (78%)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>84/113<br>
  (74%)</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>97/138<br>
  (70%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P&gt;0.05<sup>&#8225;</sup></p>
  </td>
  <td width=213 colspan=2 valign=top style='width:159.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>P=0.48</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=193 valign=top style='width:144.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>Median increase in CD4
  cell count at week 48 (cells/mm<sup>3</sup>)</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>85</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>73</p>
  </td>
  <td width=106 valign=top style='width:79.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>110</p>
  </td>
  <td width=107 valign=top style='width:79.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Normal11pt0 style='page-break-after:avoid'>106</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:24.0pt;text-indent:-24.0pt;page-break-after:
avoid'>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For both studies: For patients entering study
with VL&nbsp;&lt;&nbsp;200&nbsp;copies/ml, VF defined as <u>&gt;</u>&nbsp;200&nbsp;copies/ml.
MaxCmin1: For those entering with VL&nbsp;<u>&gt;</u>&nbsp;200 copies/ml, VF
defined as any increase <u>&gt;</u>&nbsp;0.5&nbsp;logs and/or VL&nbsp;<u>&gt;&nbsp;</u>50,000
copies/ml at week 4, <u>&gt;&nbsp;</u>5,000&nbsp;copies/ml at week 12, or <u>&gt;</u>&nbsp;200&nbsp;copies/ml
at week 24 or thereafter. MaxCmin2: any rise <u>&gt;</u>&nbsp;0.5&nbsp;log at a
specific visit; <u>&lt;</u>&nbsp;0.5&nbsp;log reduction if VL&nbsp;<u>&gt;</u>&nbsp;200&nbsp;copies/ml
at week 4; <u>&lt;</u>&nbsp;1.0&nbsp;log reduction from base line if VL&nbsp;<u>&gt;</u>&nbsp;200&nbsp;copies/ml
at week 12; and a VL&nbsp;<u>&gt;</u>&nbsp;200 copies/ml at week 24.</p>

<p class=MsoNormal style='margin-left:24.0pt;text-indent:-24.0pt'><sup>#</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ITT/e
= Intent-to-treat/exposed</p>

<p class=MsoNormal style='margin-left:24.0pt;text-indent:-24.0pt'><sup>&#8224;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Data
from clinical study report</p>

<p class=MsoNormal style='margin-left:24.0pt;text-indent:-24.0pt'><sup>&#8225;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Data
from<b> </b>MaxCmin1 publication</p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Clinical results from paediatric
studies</span></i></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>The pharmacokinetics, safety and activity of saquinavir have
been evaluated in an open label, multicenter study in 18 children aged 4 months
to less than 6 years old in which saquinavir (50&nbsp;mg/kg bid up to the adult
dose of 1000&nbsp;mg bid) was administered in combination with ritonavir oral
solution (3&nbsp;mg/kg bid for body weight from 5 to &lt;15&nbsp;kg,
2.5&nbsp;mg/kg bid for body weight from 15 to 40&nbsp;kg and 100&nbsp;mg bid
for body weight &gt;40&nbsp;kg) plus &#8805;2 background ARVs. The infants and
young children were stratified into 2 groups: Group A &#8220;Low Age
Group&#8221; 4 months to less than 2 years old (n=5) and Group B &#8220;High
Age Group&#8221; children 2 years to less than 6 years old (n=13). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In the &#8220;High Age Group&#8221;, the number of patients
with a viral load &lt;400 copies/mL at week 48 was 11 of 13.&nbsp; The number
of patients with viral load &lt;50 copies/mL was 9 of 13 for the same
period.&nbsp; The CD4 lymphocyte count expressed as percentage mean CD4
increased by a mean of 2.97% over the same 48 week period. The size of the
study was too small to allow conclusions on clinical benefit.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic properties</span></b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Saquinavir is essentially completely metabolised by CYP3A4.
Ritonavir inhibits the metabolism of saquinavir, thereby increasing
(&quot;boosting&quot;) the plasma levels of saquinavir. </p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Absorption:</span></i></b><span
lang=EN-GB> In HIV-infected adult patients, Invirase in combination with
ritonavir at doses of 1000/100&nbsp;mg twice daily provides saquinavir systemic
exposures over a 24-hour period similar to or greater than those achieved with saquinavir
soft capsules 1200&nbsp;mg tid (see Table 8). The pharmacokinetics of
saquinavir is stable during long-term treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:42.55pt;text-indent:-42.55pt;page-break-after:
avoid'><span lang=EN-GB>Table 8: Mean (% CV) AUC, C<sub>max</sub> and C<sub>min</sub>
of saquinavir in patients following multiple dosing of Invirase, saquinavir
soft capsules, Invirase/ritonavir, and saquinavir soft capsules/ritonavir</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Treatment</span></b></p>
  </td>
  <td width=38 valign=top style='width:.4in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>N</span></b></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>AUC&#964; (ng&middot;h/ml)</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>AUC<sub>0-24 </sub>(ng&middot;h/ml)</span></b><sup>
  &#8224;</sup></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>C<sub>max</sub></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(ng/ml)</span></b></p>
  </td>
  <td width=103 valign=top style='width:77.35pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>C<sub>min</sub></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(ng/ml)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Invirase </span>(hard
  capsule)<span lang=EN-GB><br>
  600&nbsp;mg tid</span></p>
  </td>
  <td width=38 valign=top style='width:.4in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoEndnoteText align=center style='text-align:center;line-height:
  13.0pt;page-break-after:avoid'><span lang=EN-GB>10</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>866 (62)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2,598</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>197 (75)</span></p>
  </td>
  <td width=103 valign=top style='width:77.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>75 (82)</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR-CH>saquinavir
  soft capsule</span><span lang=FR-CH><br>
  1200&nbsp;mg tid</span></p>
  </td>
  <td width=38 valign=top style='width:.4in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>31</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>7,249 (85)</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>21,747</span></p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>2,181 (74)</span></p>
  </td>
  <td width=103 valign=top style='width:77.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>216 (84)</span></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Invirase </span>(tablet)<br>
  <span lang=EN-GB>1000&nbsp;mg bid plus ritonavir 100&nbsp;mg bid*<br>
  (fasting condition)</span></p>
  </td>
  <td width=38 valign=top style='width:.4in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>22</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>10,320</p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>(2,530-30,327)</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>20,640</p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1,509</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(355-4,101)</span></p>
  </td>
  <td width=103 valign=top style='width:77.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>313</p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>(70-1,725)<sup> &#8224;&#8224;</sup></p>
  </td>
 </tr>
 <tr>
  <td width=168 valign=top style='width:125.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Invirase </span>(tablet)<br>
  <span lang=EN-GB>1000&nbsp;mg bid plus ritonavir 100&nbsp;mg bid*<br>
  (high fat meal)</span></p>
  </td>
  <td width=38 valign=top style='width:.4in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>22</span></p>
  </td>
  <td width=122 valign=top style='width:91.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>34,926</p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>(11,826-105,992)</p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>69,852</p>
  </td>
  <td width=102 valign=top style='width:76.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>5,208</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>(1,536-14,369)</span></p>
  </td>
  <td width=103 valign=top style='width:77.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>1,179</p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>(334-5,176)<sup> &#8224;&#8224;</sup></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&#964; =
dosing interval, i.e. 8 hour for tid and 12 h for bid dosing.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>C</span><sub><span
lang=EN-GB style='font-family:"Times",serif'>min</span></sub><span lang=EN-GB>
= the observed plasma concentration at the end of the dose interval.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>bid = twice
daily</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>tid = three
times daily</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>* results
are geometric mean (min - max) </span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup>&#8224; </sup><span
lang=EN-GB>derived from tid or bid dosing schedule</span></p>

<p class=MsoNormal style='page-break-after:avoid'><sup>&#8224;&#8224; </sup><span
lang=EN-GB>C<sub>trough</sub></span><span lang=EN-GB> values</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Absolute bioavailability averaged 4&nbsp;%
(CV 73&nbsp;%, range: 1&nbsp;% to 9&nbsp;%) in 8 healthy volunteers who
received a single 600&nbsp;mg dose (3 x 200&nbsp;mg</span> hard capsule<span
lang=EN-GB>) of Invirase following a heavy breakfast. The low bioavailability
is thought to be due to a combination of incomplete absorption and extensive
first-pass metabolism. Gastric pH has been shown to be only a minor component
in the large increase in bioavailability seen when given with food. The
absolute bioavailability of saquinavir co-administered with ritonavir has not
been established in humans.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In combination with ritonavir,
bioequivalence of Invirase hard capsules and film-coated tablets was
demonstrated under fed conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Effective therapy in treatment na&iuml;ve
patients is associated with a C<sub>min</sub> of approximately 50&nbsp;ng/ml
and an AUC<sub>0-24</sub> of about 20,000&nbsp;ng&middot;h/ml. <span
style='layout-grid-mode:line'>Effective therapy in treatment experienced
patients is associated with a C<sub>min</sub> of approximately 100 ng/ml and an
AUC<sub>0-24</sub> of about 20,000&nbsp;ng</span>&middot;<span
style='layout-grid-mode:line'>h/ml.</span></span></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal>In treatment-na&iuml;ve HIV-1 infected patients initiating
Invirase/ritonavir treatment with a modified Invirase/ritonavir dosing regimen
of <span lang=EN-GB>Invirase 500&nbsp;mg two times daily with ritonavir
100&nbsp;mg two times daily for the first 7 days of treatment and increased to
Invirase 1000&nbsp;mg two times daily with ritonavir 100&nbsp;mg two times
daily in the subsequent 7 days, </span>saquinavir systemic exposures generally
approached or exceeded the range of historical steady-state values with the
standard Invirase/ritonavir 1000&nbsp;mg/100&nbsp;mg bid dosing regimen across
study days <span lang=EN-GB>(see Tables 9 and 8)</span>. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Table 9: Mean (CV%) PK Parameters following administration
of the Modified Invirase/ritonavir Regimen in Treatment Na&iuml;ve HIV-1
infected Patients initiating treatment with Invirase/ritonavir</p>

<div align=right>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=620
 style='width:465.15pt;border-collapse:collapse;border:none'>
 <tr style='height:36.95pt'>
  <td width=107 valign=top style='width:80.6pt;border:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Parameter</b></p>
  </td>
  <td width=105 valign=top style='width:78.45pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Day 3</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=22)</b></p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Day 4</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Day 7</b></p>
  <p class=MsoNormal><b>500/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Day 10</b></p>
  <p class=MsoNormal><b>1000/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border:solid black 1.0pt;
  border-left:none;padding:.05in 7.8pt .05in 7.8pt;height:36.95pt'>
  <p class=MsoNormal><b>Day 14</b></p>
  <p class=MsoNormal><b>1000/100 mg</b></p>
  <p class=MsoNormal><b>(n=21)</b></p>
  </td>
 </tr>
 <tr style='height:15.2pt'>
  <td width=107 valign=top style='width:80.6pt;border:solid black 1.0pt;
  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:15.2pt'>
  <p class=MsoNormal>AUC<sub>0-12</sub><b><sub> </sub></b><b><span lang=EN-GB>(ng*hr/ml)</span></b></p>
  </td>
  <td width=105 valign=top style='width:78.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt'>
  <p class=MsoNormal>27100 (35.7)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:15.2pt'>
  <p class=MsoNormal>20300 (39.9)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:15.2pt'>
  <p class=MsoNormal>12600 (54.5)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt'>
  <p class=MsoNormal>34200 (48.4)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:15.2pt'>
  <p class=MsoNormal>31100 (49.6)</p>
  </td>
 </tr>
 <tr style='height:13.3pt'>
  <td width=107 valign=top style='width:80.6pt;border:solid black 1.0pt;
  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>C<sub>max</sub> (ng/ml)</p>
  </td>
  <td width=105 valign=top style='width:78.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>4030 (29.1)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:13.3pt'>
  <p class=MsoNormal>2960 (40.2)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:13.3pt'>
  <p class=MsoNormal>1960 (53.3)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>5300 (36.0)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>4860 (46.8)</p>
  </td>
 </tr>
 <tr style='height:13.3pt'>
  <td width=107 valign=top style='width:80.6pt;border:solid black 1.0pt;
  border-top:none;padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>C<b><sub><span lang=EN-GB>12</span></sub></b><b><span
  lang=EN-GB> (ng/ml)</span></b></p>
  </td>
  <td width=105 valign=top style='width:78.45pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>899 (64.9)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:13.3pt'>
  <p class=MsoNormal>782 (62.4)</p>
  </td>
  <td width=99 valign=top style='width:73.9pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:.05in 7.8pt .05in 7.8pt;
  height:13.3pt'>
  <p class=MsoNormal>416 (98.5)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>1220 (91.6)</p>
  </td>
  <td width=106 valign=top style='width:79.15pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:.05in 7.8pt .05in 7.8pt;height:13.3pt'>
  <p class=MsoNormal>1120 (80.9)</p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>In vitro</span></i><span lang=EN-GB>
studies have shown that saquinavir is a substrate for P-glycoprotein (P-gp).</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Effect of food:</span></i></b><span
lang=EN-GB> </span>In a cross-over study in 22 HIV-infected patients treated
with Invirase/ritonavir 1000&nbsp;mg/100&nbsp;mg twice daily and receiving
three consecutive doses under fasting conditions or after a high-fat,
high-calorie meal (46 g fat, 1,091 Kcal), the AUC<sub>0-12</sub>, C<sub>max</sub>
and C<sub>trough</sub> values of saquinavir under fasting conditions were about
70 per cent lower than with a high-fat meal. All but one of the patients
achieved C<sub>trough</sub> values of saquinavir above the therapeutic
threshold (100 ng/ml) in the fasted state. There were no clinically significant
differences in the pharmacokinetic profile of ritonavir in fasting and fed
conditions but the ritonavir C<sub>trough</sub> (geometric mean 245 vs. 348
ng/ml) was lower in the fasting state compared to the administration with a
meal. Invirase/ritonavir should be administered with or after food.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Distribution in adults:</span></i></b><span
lang=EN-GB> Saquinavir partitions extensively into the tissues. The mean
steady-state volume of distribution following intravenous administration of a
12&nbsp;mg dose of saquinavir was 700&nbsp;l (CV 39&nbsp;%). It has been shown
that saquinavir is approximately 97&nbsp;% bound to plasma proteins up to
30&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/ml. In two patients receiving Invirase 600&nbsp;mg three times
daily, cerebrospinal fluid concentrations of saquinavir were negligible when
compared to concentrations from matching plasma samples.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Biotransformation and elimination in
adults:</span></i></b><b><span lang=EN-GB> </span></b><i><span lang=EN-GB>In
vitro</span></i><span lang=EN-GB> studies using human liver microsomes have
shown that the metabolism of saquinavir is cytochrome P450 mediated with the
specific isoenzyme, CYP3A4, responsible for more than 90&nbsp;% of the hepatic
metabolism. Based on <i>in vitro</i> studies, saquinavir is rapidly metabolised
to a range of mono- and di-hydroxylated inactive compounds. In a mass balance
study using 600&nbsp;mg 14C-saquinavir (n = 8), 88&nbsp;% and 1&nbsp;% of the
orally administered radioactivity, was recovered in faeces and urine, respectively,
within 4 days of dosing. In an additional four subjects administered
10.5&nbsp;mg 14C-saquinavir intravenously, 81&nbsp;% and 3&nbsp;% of the
intravenously administered radioactivity was recovered in faeces and urine,
respectively, within 4&nbsp;days of dosing. 13&nbsp;% of circulating saquinavir
in plasma was present as unchanged compound after oral administration and the
remainder as metabolites. Following intravenous administration 66&nbsp;% of
circulating saquinavir was present as unchanged compound and the remainder as
metabolites, suggesting that saquinavir undergoes extensive first pass
metabolism. <i>In vitro</i> experiments have shown that the hepatic metabolism
of saquinavir becomes saturable at concentrations above 2 </span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml.</span></p>

<p class=MsoNormal><span lang=EN-GB>Systemic clearance of saquinavir was high,
1.14 l/h/kg (CV 12&nbsp;%), slightly above the hepatic plasma flow, and
constant after intravenous doses of 6, 36 and 72&nbsp;mg. The mean residence
time of saquinavir was 7 hours (n = 8).</span></p>

<p class=MsoNormal><b><i><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i><u><span lang=EN-GB>Special
populations</span></u></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i>&nbsp;</i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><i>Effect of gender
following treatment with Invirase/ritonavir:</i></b> A gender difference was
observed with females showing higher saquinavir exposure than males (AUC on
average 56&nbsp;% higher and C<sub>max</sub> on average 26&nbsp;% higher) in
the bioequivalence study comparing Invirase 500&nbsp;mg film coated tablets
with Invirase 200&nbsp;mg hard capsules both in combination with ritonavir.
There was no evidence that age and body-weight explained the gender difference
in this study. Limited data from controlled clinical studies with the approved
dosage regimen do not indicate a major difference in the efficacy and safety
profile between men and women.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><i>Patients with hepatic impairment: </i></b>The effect
of hepatic impairment on the steady state pharmacokinetics of
saquinavir/ritonavir (1000&nbsp;mg/100&nbsp;mg twice daily for 14 days) was
investigated in 7 HIV-infected patients with moderate liver impairment (Child
Pugh Grade B score 7 to 9). The study included a control group consisting of 7
HIV-infected patients with normal hepatic function matched with the hepatically
impaired patients for age, gender, weight and tobacco use. The mean
(%&nbsp;coefficient of variation in parentheses) values for saquinavir AUC<sub>0-12</sub>
and C<sub>max</sub> were 24.3 (102%)&nbsp;&micro;g&middot;hr/ml and 3.6 (83%)
&micro;g/ml, respectively, for HIV-infected patients with moderate hepatic
impairment. The corresponding values in the control group were 28.5 (71%)
&micro;g&middot;hr/ml and 4.3 (68%)&nbsp;&micro;g/ml. The geometric mean ratio
(ratio of pharmacokinetic parameters in hepatically impaired patients to
patients with normal liver function) (90% confidence interval) was 0.7 (0.3 to
1.6) for both AUC<sub>0-12</sub> and C<sub>max</sub>, which suggests
approximately 30% reduction in the pharmacokinetic exposure in patients with
moderate hepatic impairment. Results are based on total concentrations
(protein-bound and unbound). Concentrations unbound at steady-state were not
assessed. No dosage adjustment seems warranted for patients with moderate
hepatic impairment based on limited data. Close monitoring of safety (including
signs of cardiac arrhythmia) and of virologic response is recommended due to
increased variability of the exposure in this population<i><span
style='font-size:10.0pt;font-family:"Arial",sans-serif'> </span></i><span
lang=EN-GB>(see sections 4.2 and 4.4)</span>.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>Paediatric
Patients</span></i></b><span lang=EN-GB>: Steady state pharmacokinetic
information is available from HIV-infected paediatric patients from study
NV20911. In this study, 5 patients were &lt;2 years and 13 between 2 to &lt;6
years and received 50&nbsp;mg/kg saquinavir bid (not to exceed 1000&nbsp;mg
bid) boosted with ritonavir at 3&nbsp;mg/kg for patients with body weight
ranging from 5 to &lt;15&nbsp;kg or 2.5&nbsp;mg/kg for patients with body
weight ranging from 15 to 40&nbsp;kg (not to exceed 100&nbsp;mg bid).</span><span
lang=EN-GB> Sixteen of 18 children could not swallow Invirase hard capsules and
received medication by opening the capsules and mixing the contents with
different vehicles.</span><span lang=EN-GB> The pharmacokinetic exposure
parameters for </span><span lang=EN-GB>the &#8220;High Age Group&#8221; </span><span
lang=EN-GB>are listed in Table 10. </span><span lang=EN-GB>Results of the
&#8220;Low Age Group&#8221; are not shown as data are limited due to the small
size of the group.</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-family:TimesNewRomanPSMT'>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Table&nbsp;10:
Pharmacokinetic parameters of saquinavir at steady-state in HIV-infected
pediatric patients</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=295 colspan=3 valign=top style='width:221.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;text-align:justify;text-justify:
  inter-ideograph;line-height:14.0pt'>&nbsp;</p>
  </td>
  <td width=295 colspan=3 valign=top style='width:221.4pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'><b>Mean &plusmn; SD Saquinavir (%CV) Pharmacokinetic
  Parameters*</b></p>
  </td>
 </tr>
 <tr>
  <td width=127 valign=top style='width:95.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;text-align:justify;text-justify:
  inter-ideograph;line-height:14.0pt'><b>Study</b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><b>Age</b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'><b>Group</b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:14.0pt'>(Years)</p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'><b>N</b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'><b>AUC<sub>0-12h</sub> (ng&#8226;h/mL)</b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'><b>C<sub>trough</sub> (ng/mL)</b></p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'><b>C<sub>max </sub>(ng/mL)</b></p>
  </td>
 </tr>
 <tr>
  <td width=127 valign=top style='width:95.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-bottom:8.5pt;text-align:justify;text-justify:
  inter-ideograph;line-height:14.0pt'>NV20911</p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>2 to &lt; 6 years</p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>13</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>38000 &plusmn; 18100</p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>(48%)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>1860 &plusmn; 1060</p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>(57%)</p>
  </td>
  <td width=98 valign=top style='width:73.8pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>5570 &plusmn; 2780</p>
  <p class=MsoNormal align=center style='margin-bottom:8.5pt;text-align:center;
  line-height:14.0pt'>(50%)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>* All parameters normalized to a 50&nbsp;mg/kg dose</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span style='color:black'>Steady state saquinavir exposures
observed in paediatric trials were substantially higher than historical data in
adults where dose- and exposure-dependent QTc and PR prolongation were observed
(see section 4.4).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical safety data</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>A<i>cute
and chronic toxicity:</i></span></b><span lang=EN-GB> Saquinavir was well
tolerated in oral acute and chronic toxicity studies in mice, rats, dogs and
marmosets.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Mutagenesis:</span></i></b><i><span
lang=EN-GB> </span></i>Mutagenicity and genotoxicity studies, with and without
metabolic activation where appropriate, have shown that saquinavir has no
mutagenic activity <i>in vitro</i> in either bacterial (Ames test) or mammalian
cells (Chinese hamster lung V79/HPRT test). Saquinavir does not induce
chromosomal damage <i>in vivo</i> in the mouse micronucleus assay or <i>in
vitro</i> in human peripheral blood lymphocytes and does not induce primary DNA
damage <i>in vitro</i> in the unscheduled DNA synthesis test.</p>

<p class=MsoNormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Carcinogenesis:</span></i></b><i><span
lang=EN-GB> </span></i><span lang=EN-GB>There was no evidence of carcinogenic
activity after the administration of saquinavir mesilate for 96 to 104 weeks to
rats and mice. The plasma exposures (AUC values) in </span>rats (maximum dose
1000&nbsp;mg/kg/day) and in mice (maximum dose 2500&nbsp;mg/kg/day) were lower
than<span lang=EN-GB> the expected plasma exposures obtained in humans at the
recommended clinical dose of ritonavir boosted Invirase. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>Reproductive toxicity:</span></i></b><i><span
lang=EN-GB> </span></i><span lang=EN-GB>Fertility, peri- and postnatal
development were not affected, and e</span>mbryotoxic / teratogenic effects
were not observed in rats or rabbits at plasma exposures lower than those
achieved in humans <span lang=EN-GB style='layout-grid-mode:line'>at the
recommended clinical dose</span> of <span lang=EN-GB>ritonavir boosted
Invirase. Distribution studies in these species showed that the placental transfer
of saquinavir is low (less than 5% of maternal plasma concentrations).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b><i><span lang=EN-GB>Safety
pharmacology:</span></i></b><b><span lang=EN-GB> </span></b><span lang=EN-GB>C</span><span
lang=EN-GB>loned human cardiac potassium channel (hERG) trafficking <i>in vitro</i>
was inhibited by 75% at 30</span><span lang=DE>&#956;</span><span lang=EN-GB>M
of saquinavir. Saquinavir inhibited both hERG current and L-type Ca++ channel
current with respective IC50s of 4.7 and 6.3 </span><span lang=DE>&#956;</span><span
lang=EN-GB>M. In a myocardial distribution study in the rat an approximately
2-fold accumulation of saquinavir was observed in the heart compared to plasma
after coadministration of saquinavir and ritonavir. The clinical relevance of
these preclinical results are unknown, however cardiac conduction and
repolarisation abnormalities in humans have been observed with saquinavir and
ritonavir combination therapy (see section 4.4 and 5.1).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB style='text-transform:uppercase'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Tablet core: </i></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=IT>Microcrystalline
cellulose,</span></p>

<p class=MsoNormal><span lang=IT>Croscarmellose sodium,</span></p>

<p class=MsoNormal><span lang=IT>Povidone,</span></p>

<p class=MsoNormal>Lactose (monohydrate),</p>

<p class=MsoNormal>Magnesium stearate.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Tablet coat:</i></p>

<p class=MsoNormal><span lang=IT>Hypromellose,</span></p>

<p class=MsoNormal><span lang=IT>Titanium dioxide (E 171),</span></p>

<p class=MsoNormal><span lang=IT>Talc,</span></p>

<p class=MsoNormal><span lang=ES>Glycerol triacetate,</span></p>

<p class=MsoNormal>Iron oxide yellow and red (E172).</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><span lang=EN-GB>3 years.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for storage</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>This medicinal product does not require any
special storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of container</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Plastic bottles (HDPE) containing 120 tablets.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for disposal</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>No special requirements for disposal.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION
NUMBER </span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/96/026/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Date of
first authorisation: 04 October 1996</span></p>

<p class=MsoNormal><span lang=EN-GB>Date of latest renewal: 04 October 2006</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal>Detailed information on this product is available on the
website of the European Medicines Agency <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S) RESPONSIBLE FOR
BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR </span></b><b>RESTRICTIONS REGARDING &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUPPLY
AND USE</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt'><b>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <span
style='text-transform:uppercase'>conditions or restrictions with regard to the
safe and effective use of the medicinal product</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:56.7pt;margin-bottom:.0001pt'><b>&nbsp;</b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=AnnexHeading><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='margin-right:70.8pt;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>Name and address of the manufacturer
responsible for batch release</span></u></p>

<p class=MsoNormal style='margin-right:70.8pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Pharma AG<br>
Emil-Barell-Str. </span><span lang=EN-GB>1,<br>
79639 Grenzach-Wyhlen,<br>
Germany.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to restricted
medical prescription (See Annex I: Summary of Product Characteristics, section
4.2).</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER </span>CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</p>

<p class=MsoNormal style='text-autospace:none'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:13.0pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b>Periodic
Safety Update Reports </b></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>The
requirements for submission of periodic safety update reports for this
medicinal product are set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent
updates published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=AnnexHeading><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT&nbsp; </span></p>

<p class=MsoNormal style='margin-right:-.05pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:13.0pt;
text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;</span><span
lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><b>Risk
Management Plan (RMP)</b></p>

<p class=MsoNormal style='text-autospace:none'>The MAH shall perform the
required pharmacovigilance activities and interventions detailed in the agreed
RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed
subsequent updates of the RMP.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>An updated RMP should be
submitted:</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;text-autospace:
none'>-&nbsp;&nbsp;&nbsp;&nbsp; At the request of the European Medicines
Agency;</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;text-autospace:
none'>-&nbsp;&nbsp;&nbsp;&nbsp; Whenever the risk management system is
modified, especially as the result of new information being received that may lead
to a significant change to the benefit/risk profile or as the result of an
important (pharmacovigilance or risk minimisation) milestone being reached.</p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in;text-autospace:
none'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.05pt'>&nbsp;</p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.05pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>ANNEX
III</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>LABELLING
AND PACKAGE LEAFLET</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='background:white'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE OUTER PACKAGING </span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
style='color:black'>TEXT FOR THE OUTER CARTON</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase 500&nbsp;mg </span>film-coated
tablets</p>

<p class=MsoNormal><span lang=EN-GB>Saquinavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each </span>film-coated tablet<span
lang=EN-GB> contains 500&nbsp;mg of saquinavir as saquinavir mesilate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also contains lactose (</span>monohydrate<span
lang=EN-GB>) </span>38.5&nbsp;<span lang=EN-GB>mg, colourants (titanium dioxide
E 171, iron oxide E 172) and other constituents. See package leaflet for
further information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>120 film-coated tablets</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets should be swallowed
whole</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/96/026/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>invirase 500&nbsp;mg</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:silver'>&lt;2D barcode
carrying the unique identifier included.&gt;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>PC: </span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>SN: </span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>NN: </span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
lang=EN-GB style='color:black'>PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING</span></b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='background:white;border:none;padding:0in'><b><span
style='color:black'>TEXT FOR THE BOTTLE LABEL </span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase 500&nbsp;mg </span>film-coated
tablets</p>

<p class=MsoNormal><span lang=EN-GB>Saquinavir</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Each </span>film-coated tablet<span
lang=EN-GB> contains 500&nbsp;mg of saquinavir as saquinavir mesilate.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Also contains lactose (</span>monohydrate<span
lang=EN-GB>) </span>38.5&nbsp;<span lang=EN-GB>mg, colourants (titanium dioxide
E 171, iron oxide E 172) and other constituents. See package leaflet for further
information.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>120 film-coated tablets</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Oral use</span></p>

<p class=MsoNormal><span lang=EN-GB>The film-coated tablets should be swallowed
whole</span></p>

<p class=MsoNormal><span lang=EN-GB>Read the package leaflet before use</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Keep out of the sight and reach of children</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>EU/1/96/026/002</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Batch</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicinal product subject to medical
prescription</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:white'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;background:
white;border:none;padding:0in'><b><span lang=EN-GB style='color:black'>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN
BRAILLE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Not applicable</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Annex><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>Package Leaflet:
Information for the user</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Invirase
500&nbsp;mg </span>film-coated tablet</b><b><span lang=EN-GB>s</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span lang=EN-GB>Saquinavir</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine </span>because it
contains important information for you</b><b><span lang=EN-GB>.</span></b></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp; Keep
this leaflet. You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp; If
you have any further questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only. Do not pass it on to others. It may
harm them, even if their signs of illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If you get any
side effects, talk to your doctor or pharmacist. This includes any possible
side effects not listed in this leaflet. See section 4.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=MsoNormal><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Invirase is and what it is used for</span></p>

<p class=MsoNormal><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>What
you need to know b<span lang=EN-GB>efore you take Invirase</span></p>

<p class=MsoNormal><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take Invirase</span></p>

<p class=MsoNormal><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></p>

<p class=MsoNormal><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Invirase</span></p>

<p class=MsoNormal><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span>Contents
of the pack and other <span lang=EN-GB>information</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Invirase
is and what it is used for</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase contains the active substance saquinavir
which is an antiviral agent. It is a member of a class of medicines called
protease inhibitors. It is for the treatment of infection with the human
immunodeficiency virus (HIV).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase is used by HIV-1-infected adults.
Invirase is prescribed for use in combination with ritonavir (Norvir) and other
antiretroviral medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Invirase</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Do not
take Invirase if you have:</span></b></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an
allergy to saquinavir, ritonavir or any of the other ingredients</span> (see
&#8220;Invirase contains lactose&#8221; later in this section and &#8220;What
Invirase contains&#8221; in Section 6)</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol;color:black'>&middot;</span><span style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any
heart problems that show on an electrocardiogram (ECG, electrical recording of
the heart)</span><span lang=EN-GB> - you may have been born with that</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol;color:black'>&middot;</span><span style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
very slow heart rate (bradycardia)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol;color:black'>&middot;</span><span style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
weak heart (heart failure)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol;color:black'>&middot;</span><span style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a
history of an irregular heart beat (arrhythmias)</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol;color:black'>&middot;</span><span style='color:black'>&nbsp;&nbsp;&nbsp;&nbsp; a
salt imbalance in your blood, especially low blood concentrations of potassium
(hypokalaemia), which is not currently controlled by treatment</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; severe
liver problems such as jaundice, hepatitis</span> or liver failure - where your
belly fills with fluid, you get confused or your oesophagus (the tube that runs
from your mouth to your stomach) bleeds</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; recently
taken the HIV medicine rilpivirine</span>.</p>

<p class=MsoNormal>Do not take Invirase if any of the above applies to you. If
you are not sure, talk to your doctor or pharmacist before taking Invirase.</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Do not take Invirase <span
style='color:black'>if you are taking any of the following medicines:</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span style='color:black'>Any
medicine that can change your heart beat, </span></b><span style='color:black'>such
as:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;</span><span
lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines for HIV - such as
atazanavir, lopinavir, rilpivirine</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
heart medicines - </span>amiodarone, bepridil, disopyramide, dofetilide,
flecainide, hydroquinidine, ibutilide, lidocaine, propafenone, quinidine,
sotalol</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines for depression - amitriptyline, imipramine, trazodone, maprotiline</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
for other severe mental health problems - such as </span>clozapine, haloperidol,<br>
mesoridazine, phenothiazines, sertindole, sultopride, thioridazine, ziprasidone</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines for infection - such as clarithromycin, dapsone, erythromycin,
halofantrine, pentamidine, sparfloxacin</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
strong pain killers (narcotics)</span> - such as alfentanyl, fentanyl, methadone</p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; medicines
for erectile dysfunction - sildenafil, vardenafil, tadalafil</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines that may be used for a variety of things: cisapride, diphemanil,
mizolastine, quinine, vincamine.</p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; </span>certain
medicines used to prevent rejection of new organs after a transplant operation
such as tacrolimus</p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp; certain medicines
used to treat the symptoms of Benign Prostatic Hyperplasia (an increase in size
of the prostate) such as alfuzosin</p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines <span lang=EN-GB>commonly used for allergy symptoms such as terfenadine
and astemizole</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines <span lang=EN-GB>for severe mental health problems such as pimozide </span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp; certain
medicines <span lang=EN-GB>(so called tyrosine kinase inhibitors) used to treat
different types of cancer such as dasatinib and sunitinib</span>.</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>Any of these other medicines:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ergot
alkaloids - for migraine attacks</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triazolam
and midazolam </span>(taken by mouth)<span lang=EN-GB> - to help you sleep or
for anxiety</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin
- for preventing or treating tuberculosis</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin
and lovastatin - for lowering blood cholesterol</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>quetiapine &#8211; used to treat schizophrenia, bipolar disorder and
major depressive disorder</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp; </span><span
lang=EN-GB>lurasidone &#8211; used to treat schizophrenia.</span></p>

<p class=MsoNormal style='margin-left:21.3pt;text-indent:-21.3pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take Invirase with any other drug
unless you have talked to your doctor first.&nbsp; The drugs listed above might
cause serious side effects if you take them together with Invirase.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Do not take Invirase if any of the above
applies to you. If you are not sure, talk to your doctor or pharmacist before
taking Invirase.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Warnings
and precautions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>You should know that Invirase/ritonavir is
not a cure for HIV infection and that you may continue to develop infections or
other illnesses associated with HIV disease. You should, therefore, remain
under the care of your doctor while taking Invirase/ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You can still pass on HIV when taking this
medicine, although the risk is lowered by effective antiretroviral therapy.
Discuss with your physician the precautions needed to avoid infecting other
people.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>At present, there is only limited
information on the use of Invirase/ritonavir in children and in adults over the
age of 60&nbsp;years.</span></p>

<p class=MsoNormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal><b><u>Abnormal heart rhythms (arrhythmias):</u></b></p>

<p class=MsoNormal>Invirase can change how your heart beats - this can be
serious. This can happen especially if you are female or elderly. </p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you
are taking any medicine that decreases your blood potassium levels talk to your
doctor before taking Invirase. </p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><b><span
style='font-family:Symbol'>&middot;</span></b><b>&nbsp;&nbsp;&nbsp;&nbsp; Contact
your doctor immediately, if you get palpitations or an irregular heart beat
during treatment.</b> Your doctor may wish to do an ECG to check your heart
beat.</p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><b><span lang=EN-GB>Other conditions</span></b></p>

<p class=MsoNormal><span lang=EN-GB>There are certain conditions, which you may
have, or have had, which require special care before or while taking
Invirase/ritonavir. Therefore, before taking this medicine, you should have
told your doctor if you suffer from diarrhoea, or if you have allergies (see
Section 4)</span> or if you have an intolerance to some sugars (see section &#8220;Invirase
contains lactose&#8221;)<span lang=EN-GB>.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Kidney
disease: Consult your doctor if you have a history of kidney disease.</span></p>

<p class=MsoNormal style='page-break-after:avoid'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Liver
disease: Please speak with your doctor if you have a history of liver disease.
Patients with chronic hepatitis B or C and treated with antiretroviral agents
are at increased risk of severe and potentially fatal liver adverse events and
may require blood tests for control of liver function.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Infection: In some patients with advanced HIV infection
(AIDS) and a history of opportunistic infection, signs and symptoms of
inflammation from previous infections may occur soon after anti-HIV treatment
is started. It is believed that these symptoms are due to an improvement in the
body&#8217;s immune response, enabling the body to fight infections that may
have been present with no obvious symptoms. If you notice any symptoms of
infection, please inform your doctor immediately (see Section 4).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=EN-GB>In addition to the opportunistic
infections, autoimmune disorders (a condition that occurs when the immune
system attacks healthy body tissue) may also occur after you start taking
medicines for the treatment of your HIV infection. Autoimmune disorders may
occur many months after the start of treatment. If you notice any symptoms of
infection or other symptoms such as muscle weakness, weakness beginning in the
hands and feet and moving up towards the trunk of the body, palpitations,
tremor or hyperactivity, please inform your doctor immediately to seek
necessary treatment.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Bone problems: </span><span lang=EN-GB>Some
patients taking combination antiretroviral therapy may develop a bone disease
called osteonecrosis (death of bone tissue caused by loss of blood supply to
the bone). The length of combination antiretroviral therapy, corticosteroid
use, alcohol consumption, severe immunosuppression, higher body mass index,
among others, may be some of the many risk factors for developing this disease.
Signs of osteonecrosis are joint stiffness, aches and pains (especially of the
hip, knee and shoulder) and difficulty in movement. If you notice any of these
symptoms please inform your doctor. </span></p>

<p class=MsoNormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Other
medicines and Invirase</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Tell your doctor or pharmacist if you are
taking, have recently taken or might take any other medicines. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase/ritonavir <i>may be taken</i> with
a number of other medications that are commonly used in HIV infection.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB>There are some medications that must not
be taken with Invirase/ritonavir (see section &quot;Do not take Invirase if you
are taking any of the following medicines:&quot; above)</span></u><span
lang=EN-GB>. There are also some medicines that <i>require dosage reduction</i>
of that medicine or Invirase or ritonavir (see section &#8220;Medicines that
can interact with saquinavir or ritonavir include:&#8221; below). Ask your
doctor or pharmacist for more information about taking Invirase/ritonavir with
other medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Medicines that can interact with saquinavir
or ritonavir include:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other
HIV medicines - such as nelfinavir, indinavir, nevirapine, delavirdine,
efavirenz, maraviroc, cobicistat</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some
medicines affecting the immune system - such as ciclosporin, sirolimus
(rapamycin), tacrolimus</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; various
steroids - such as dexamethasone, ethinyl estradiol, fluticasone</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
heart medicines - such as calcium channel blockers, quinidine, digoxin</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
used to lower blood cholesterol - such as statins</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungals
- ketoconazole, itraconazole, fluconazole, miconazole</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticonvulsants
- such as phenobarbital, phenytoin, carbamazepine</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sedative
agents - such as midazolam administered by injection</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=FR
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain
antibiotics <span lang=EN-GB>- such as </span>quinupristin/dalfopristin,
rifabutin, fusidic acid</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
to treat depression - such as nefazodone, tricyclic antidepressants</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
for anticoagulation - warfarin</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herbal
preparations containing St. John&#8217;s wort or garlic capsules</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some
medicines that treat diseases related to the acid in the stomach <span
lang=EN-GB>- such as </span>omeprazole or other proton pump inhibitors</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
used to treat asthma or other chest illness such as Chronic Obstructive
Pulmonary Disease (COPD) such as salmeterol</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
for gout, such as colchicine</p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines
used to treat high blood pressure in the arteries of the lungs (a disease known
as pulmonary arterial hypertension) such as bosentan.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Therefore
you should not take Invirase/ritonavir with other medicines without your
doctor&#8217;s consent. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>If you are taking an oral contraceptive to
prevent pregnancy, you should use an additional or different type of
contraception since ritonavir may reduce the effectiveness of oral
contraceptives.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Invirase
with food and drink</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Invirase must be taken together with
ritonavir and with or after food. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Pregnancy
and breast-feeding</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Ask your doctor or pharmacist for advice
before taking any medicine. Inform your doctor if you are pregnant or planning
to become pregnant. This medicine should be taken during pregnancy only after
consultation with your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>You should not breast-feed your baby if you
are taking Invirase/ritonavir.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>Driving
and using machines</span></b></p>

<p class=MsoNormal>Invirase has not been tested for its effect on your ability
to drive a car or operate machinery. However, dizziness, fatigue and visual
impairment have been reported during treatment with Invirase. Do not drive or
operate machines if you experience these symptoms.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Invirase contains lactose</b></p>

<p class=MsoNormal><span lang=EN-GB>Each </span>film-coated tablet<span
lang=EN-GB> contains lactose (</span>monohydrate<span lang=EN-GB>) </span>38.5<span
lang=EN-GB>&nbsp;mg. If you have been told by your doctor that you have an
intolerance to some sugars, contact your doctor before taking this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take
Invirase</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Always take this medicine exactly as your
doctor has told you. Check with your doctor or pharmacist if you are not sure.
Invirase comes as a 500&nbsp;mg </span>film-coated tablet.<span lang=EN-GB>
Your doctor will prescribe Invirase in combination with ritonavir (Norvir) and
other HIV medicines.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How to take</span></b></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take
Invirase at the same time as your ritonavir (Norvir) capsules.</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take
your Invirase film-coated tablets with or after food.</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow
them whole with water.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>How much to take</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Standard dose</span></b></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp; Take
two 500&nbsp;mg </span>film-coated tablets<span lang=EN-GB> of Invirase twice a
day.</span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp; Take
one 100&nbsp;mg capsule of ritonavir (Norvir) twice a day. </span></p>

<p class=MsoNormal style='margin-left:.75in;text-indent:-.25in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If this
is your first medicine for HIV or the first time you are taking ritonavir
(Norvir)</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>You need to
take a lower dose of Invirase for your first week. </span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
avoid'><span lang=EN-GB>Week 1:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in;page-break-after:
avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;</span><span
lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take one 500&nbsp;mg film-coated
tablet of Invirase twice a day.</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take
one 100&nbsp;mg capsule of ritonavir (Norvir) twice a day. </span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Week 2 onwards:</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue
with the standard dose.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
take more Invirase than you should<i> </i></span></b></p>

<p class=MsoNormal><span lang=EN-GB>If you have taken more than the prescribed
dose of Invirase/ritonavir you must contact your doctor or pharmacist.</span></p>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
forget to take Invirase</span></b></p>

<p class=MsoNormal><span lang=EN-GB>Do not take a double dose to make up for a
forgotten individual dose. If you forget to take one dose, take this dose as
soon as you remember together with some food. Then go on with the regular
schedule as prescribed. Do not change the prescribed dose yourself.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>If you
stop taking Invirase<i> </i></span></b></p>

<p class=MsoNormal><span lang=EN-GB>Continue to take this medicine until your
doctor tells you otherwise.</span></p>

<p class=MsoNormal><span lang=EN-GB>If you have any further questions on the
use of this medicine, ask your doctor or pharmascist.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, </span>although not everybody
gets them<span lang=EN-GB>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>During HIV therapy there may be an increase in weight and in
levels of blood lipids and glucose. This is partly linked to restored health
and lifestyle, and in the case of blood lipids sometimes to the HIV medicines
themselves. Your doctor will test for these changes. </p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>When treating
HIV infection it is not always possible to differentiate between unwanted
effects caused by Invirase or by any other medicines you take at the same time
or by the complications of the infection. For these reasons it is very
important to inform your doctor of any change in your condition.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>The most frequently <i>(in more than ten in
a hundred persons) </i>reported side effects of saquinavir taken with ritonavir
concern the gastrointestinal tract, with feeling sick, diarrhoea, tiredness,
vomiting, wind and abdominal pain being the most common. Also, changes in
laboratory markers </span>(e.g., blood or urine tests)<span lang=EN-GB> have
been reported very commonly.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Other reported side effects (<i>in more
than one in a hundred but less than one in ten persons)</i>, which may occur
are: rash, itching, eczema and dry skin, hair loss, dry mouth, headache,
peripheral neuropathy (a disturbance of the nerves in the feet and hands that
may take the form of numbness, pins and needles, shooting or burning pain),
weakness, dizziness, libido problems, taste alteration, mouth ulcers, dry lips,
abdominal discomfort, indigestion, weight loss,constipation, increased
appetite,&nbsp; muscle spasms and shortness of breath. </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;Other less frequently reported side effects
(<i>in more than one in one thousand persons but less than one in a hundred
persons) </i>include: decreased appetite, visual disturbance, inflammation of
the liver, fits, allergic reactions, blisters, sleepiness, abnormal renal
function, inflammation of the pancreas, yellowing of the skin or whites of the
eyes caused by liver problems and Steven&#8217;s Johnson syndrome (a serious
illness with blistering of the skin, eyes, mouth and genitals). </span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>In patients with haemophilia type A and B,
there have been reports of increased bleeding while taking this treatment or
another protease inhibitor. Should this happen to you, seek immediate advice
from your doctor.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>There have been reports of muscle pain,
tenderness or weakness, particularly with combination antiretroviral therapy
including protease inhibitors and nucleoside analogues. On rare occasions these
muscle disorders have been serious (rhabdomyolysis).</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>Reporting of side effects</b></p>

<p class=MsoNormal><span lang=EN-GB>If you get any side effects, talk to your
doctor, pharmacist or nurse.&nbsp; This includes any possible side effects not
listed in this leaflet. </span>You can also report side effects directly via <span
style='background:silver'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:silver'>Appendix V</span></a><span lang=EN-GB
style='background:silver'>.</span><span lang=EN-GB> By reporting side effects
you can help provide more information on the safety of this medicine.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store
Invirase</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='page-break-after:avoid'>Do not use this medicine
after the expiry date (EXP) which is stated on the bottle and carton. The
expiry date refers to the last day of that month.</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>Invirase does not require any special
storage conditions.</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Do not throw away any medicines via wastewater or household
waste. Ask your pharmacist how to throw away medicines you no longer use. These
measures will help to protect the environment.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of
the pack and other information</span></b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b>What Invirase contains</b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
active substance is saquinavir. One </span>film-coated tablet<span lang=EN-GB>
of Invirase contains </span>500<span lang=EN-GB>&nbsp;mg of saquinavir as
saquinavir mesilate.</span></p>

<p class=MsoNormal style='margin-left:.3in;text-indent:-.3in'><span lang=EN-GB
style='font-family:Symbol'>&middot;</span><span lang=EN-GB>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The
other ingredients (excipients) are</span> microcrystalline cellulose,
croscarmellose sodium, povidone, lactose (monohydrate) 38.5&nbsp;mg, magnesium
stearate, hypromellose, titanium dioxide (E171), talc, glycerol triacetate,
iron oxide yellow (E172) and iron oxide red (E172).</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>What Invirase looks like and contents of the pack</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>Invirase 500&nbsp;mg film-coated tablet<span lang=EN-GB>s
are light orange to greyish or brownish orange tablets of oval shape with the
marking &quot;SQV 500&quot; on one side and &quot;ROCHE&quot; on the other
side. One </span>plastic (HDPE) bottle contains 120 tablets.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Marketing Authorisation
Holder and Manufacturer</b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal>Emil-Barell-Strasse 1</p>

<p class=MsoNormal>79639 Grenzach-Wyhlen</p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Manufacturer </b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Roche Pharma
AG, </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Emil-Barell-Strasse
1,</span></p>

<p class=MsoNormal>79639 Grenzach-Wyhlen,</p>

<p class=MsoNormal>Germany.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>For any
information about this medicine, please contact the local representative of the
Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>N.V. Roche
  S.A.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR>T&eacute;l/Tel:
  +32 (0) 2 525 82 11</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>UAB &#8220;Roche Lietuva&#8221;</span></p>
  <p class=MsoNormal><span lang=FI>Tel: +370 5 </span><span lang=DE-CH>2546799</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE-CH>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=BG>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>&#1056;&#1086;&#1096;
  &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>&#1058;&#1077;&#1083;:
  +359 2&nbsp;818 44 44</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>(Voir/siehe
  Belgique/Belgien)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=BG>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=CS>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=CS>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=CS>Tel: +420 - 2 20382111</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Magyarorsz</b><b><span
  lang=CS>&aacute;g</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=CS>Roche
  (Magyarorsz&aacute;g) Kft.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=CS>Tel: +36 - 23
  446 800</span></p>
  <p class=MsoNormal style='text-autospace:none'>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche a/s</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tlf: +45 - 36 39 99 99</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>(See </span>Ireland<span lang=EN-GB>)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL>Nederland</span></b></p>
  <p class=MsoNormal><span lang=NL>Roche Nederland B.V.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +31 (</span><span lang=EN-GB
  style='layout-grid-mode:line'>0) 348 438050</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET>Roche Eesti O&Uuml;</span></p>
  <p class=MsoNormal><span lang=IT>Tel: + 372 - 6 177 380</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Roche Norge
  AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='layout-grid-mode:line'>Tlf: +47 -
  22 78 90 00</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche (Hellas) A.E. </span></p>
  <p class=MsoNormal><span lang=EN-GB>&#932;&#951;&#955;: +30 210 61 66 100</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Roche Farma S.A.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +34 - 91 324 81 00</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL>Roche Polska Sp.z o.o.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +48 - 22 345 18 88</span></p>
  <p class=MsoNormal><span lang=PT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-CH>France</span></b></p>
  <p class=MsoNormal><span lang=FR-CH>Roche</span></p>
  <p class=MsoNormal><span lang=FR-CH>T&eacute;l: +33 (0) 1 47 61 40 00</span></p>
  <p class=MsoNormal><b><span lang=DE-CH>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT>Roche Farmac&ecirc;utica Qu&iacute;mica, Lda</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +351 - 21 425 70 00</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche d.o.o.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: + 385 1 47 22 333</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-CH>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=FR-CH>Roche Rom&acirc;nia S.R.L.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +40 21 206 47 01</span></p>
  <p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products (Ireland) Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +353 (0) 1 469 0700</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche farmacevtska dru&#382;ba d.o.o.</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +386 - 1 360 26 00</span></p>
  <p class=MsoNormal><span lang=IT>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='layout-grid-mode:line'>&Iacute;sland
  </span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='layout-grid-mode:line'>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT-BR>S</span><span lang=CS>&iacute;</span><span
  lang=PT-BR>mi</span><span lang=PT style='layout-grid-mode:line'>: +354 540
  8000</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT>Slovensk&aacute; republika </span></b></p>
  <p class=MsoNormal><span lang=SK>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal><span lang=PT>Tel: +421 - 2 52638201</span></p>
  <p class=MsoNormal><b><span lang=PT>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +39 - 039 2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Oy<span style='layout-grid-mode:
  line'> </span></span></p>
  <p class=MsoNormal><span lang=DE-CH>Puh/Tel: +358 (0) 10 554 500</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>K</span></b><b><span lang=EL>&#973;&#960;&#961;&#959;&#962;</span></b><span
  lang=EL style='font-size:10.0pt;font-family:"Arial",sans-serif'> </span></p>
  <p class=MsoNormal><span lang=EL>&#915;.&#913;.&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;
  &amp; &#931;&#953;&#945; &#923;&#964;&#948;.</span></p>
  <p class=MsoNormal><span lang=EL>&#932;&#951;&#955;</span>: +357 - 22 76 62
  76</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche AB</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +46 (0) 8 726 1200</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 &#8211; 6 7039831</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB>United Kingdom</span></b></p>
  <p class=MsoNormal><span lang=EN-GB>Roche Products Ltd.</span></p>
  <p class=MsoNormal><span lang=EN-GB>Tel: +44 (0) 1707 366000</span></p>
  <p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.1pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal><b>Other sources of information</b></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal>Detailed information on this medicine is available on the
European Medicines Agency web site: <a href="http://www.ema.europa.eu/">http://www.ema.europa.eu</a></p>

<p class=MsoNormal><span style='color:blue'>&nbsp;</span></p>

<p class=MsoNormal>This leaflet is available in all EU/EEA languages on the
European Medicines Agency website.</p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

</div>

</body>

</html>
